

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4056321

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
TAKEDA GMBH	04/29/2016

RECEIVING PARTY DATA

Name:	ASTRAZENECA AB
Street Address:	SE-151 85
City:	SODERTALJE
State/Country:	SWEDEN

PROPERTY NUMBERS Total: 4

Property Type	Number
Patent Number:	9018175
Patent Number:	9376442
Patent Number:	8927557
Application Number:	15161702

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: patents@astrazeneca.com

Correspondent Name: KIMBERLY BRASLOW

Address Line 1: 950 WIND RIVER LANE

Address Line 4: GAITHERSBURG, MARYLAND 20878

ATTORNEY DOCKET NUMBER:	TAK1595 AND TAK1598 US
NAME OF SUBMITTER:	KIMBERLY BRASLOW
SIGNATURE:	/Kimberly Braslow/
DATE SIGNED:	09/16/2016

Total Attachments: 124

source=Assignment from Takeda Gmbh to AZ AB#page1.tif

source=Assignment from Takeda Gmbh to AZ AB#page2.tif

source=Assignment from Takeda Gmbh to AZ AB#page3.tif

source=Assignment from Takeda Gmbh to AZ AB#page4.tif

source=Assignment from Takeda Gmbh to AZ AB#page5.tif

source=Assignment from Takeda Gmbh to AZ AB#page102.tif
source=Assignment from Takeda Gmbh to AZ AB#page103.tif
source=Assignment from Takeda Gmbh to AZ AB#page104.tif
source=Assignment from Takeda Gmbh to AZ AB#page105.tif
source=Assignment from Takeda Gmbh to AZ AB#page106.tif
source=Assignment from Takeda Gmbh to AZ AB#page107.tif
source=Assignment from Takeda Gmbh to AZ AB#page108.tif
source=Assignment from Takeda Gmbh to AZ AB#page109.tif
source=Assignment from Takeda Gmbh to AZ AB#page110.tif
source=Assignment from Takeda Gmbh to AZ AB#page111.tif
source=Assignment from Takeda Gmbh to AZ AB#page112.tif
source=Assignment from Takeda Gmbh to AZ AB#page113.tif
source=Assignment from Takeda Gmbh to AZ AB#page114.tif
source=Assignment from Takeda Gmbh to AZ AB#page115.tif
source=Assignment from Takeda Gmbh to AZ AB#page116.tif
source=Assignment from Takeda Gmbh to AZ AB#page117.tif
source=Assignment from Takeda Gmbh to AZ AB#page118.tif
source=Assignment from Takeda Gmbh to AZ AB#page119.tif
source=Assignment from Takeda Gmbh to AZ AB#page120.tif
source=Assignment from Takeda Gmbh to AZ AB#page121.tif
source=Assignment from Takeda Gmbh to AZ AB#page122.tif
source=Assignment from Takeda Gmbh to AZ AB#page123.tif
source=Assignment from Takeda Gmbh to AZ AB#page124.tif

EXECUTION VERSION

Dated 29 April 2016

TAKEDA GMBH

and

ASTRAZENECA AB

**INTELLECTUAL PROPERTY RIGHTS ASSIGNMENT (PATENTS AND
DESIGNS)**

relating to the Asset Purchase Agreement dated 16 December 2016

Linklaters

Linklaters LLP
One Silk Street
London EC2Y 8HQ

Telephone (+44) 20 7456 2000
Facsimile (+44) 20 7456 2222

Ref: L-240119

LO: 989821-2

A31414557

**PATENT
REEL: 040057 FRAME: 0040**

Intellectual Property Rights Assignment (Patents and Designs)

This Agreement is made on

29 April

2016

between:

- (1) TAKEDA GMBH, a company incorporated in Germany whose registered office is at Byk-Gulden-Strasse 2, 78467 Konstanz, Germany (the "Assignor"); and
- (2) ASTRAZENECA AB, a company incorporated in Sweden with a principal place of business at 151 85, Södertälje, Sweden (the "Assignee"),
each a "Party" and together the "Parties".

Whereas:

- (A) Pursuant to the Asset Purchase Agreement, the Assignor has agreed to sell to the Assignee, and the Assignee has agreed to purchase from the Assignor, certain assets and liabilities of the Business.
- (B) In connection with the Asset Purchase Agreement and subject to, and in accordance with, the terms of this Agreement, the Assignor has agreed to assign to the Assignee, and the Assignee has agreed to accept from the Assignor, all of the Assignor's right, title and interest in and to the Assigned IPR.

It is agreed as follows:

1 Interpretation

In this Agreement, unless the context otherwise requires, the provisions in this Clause 1 shall apply:

1.1 Definitions

All capitalised terms used but not defined in this Agreement shall have the meaning given to them in the Asset Purchase Agreement.

"Assignee Abandonment Request" has the meaning given to it in Clause 3.7;

"Assignor Abandonment Notice" has the meaning given to it in Clause 3.7;

"Affiliate" means with respect to any Person, any other Person that Controls, is Controlled by or is under common Control with such Person, and "Affiliates" shall be interpreted accordingly;

"Applicable Law" means any supra-national, federal, national, state, municipal or local statute, law, ordinance, regulation, rule, guidance, code, order (whether executive, legislative, judicial or otherwise), judgment, injunction, notice, decree or other requirement or rule of law or legal process (including common law), any Court Order or any rule or requirement of any national securities exchange;

"Asset Purchase Agreement" means the asset purchase agreement between Takeda GmbH and the Assignee dated 16 December 2016;

"Assigned Designs" means all registered designs and unregistered design rights which are included within the definition of Owned Business IPR, including the registered designs listed in Schedule 2 to this Agreement;

"Assigned IPR" means the: (i) Assigned Patents; (ii) the Relevant Part of the Co-Owned Business IPR; and (iii) the Assigned Designs;

"Assigned Patents" means all Patents owned solely by the Assignor which are included within the definition of Owned Business IPR, including the Patents listed in Schedule 1 to this Agreement and the Solely-Owned 3M Business Patents;

"Assignee's Group" means the Assignee and its Affiliates;

"Assignor's Group" means the Assignor and its Affiliates;

"Assignor's Group Retained Respiratory Business" means the business of the Assignor's Group in respect of the products listed in Schedule 23 of the Asset Purchase Agreement;

"Assignor's Group Turkey Business" means the Commercialisation of Alvesco, Omnaris and Daxas in Turkey;

"Business" means the worldwide business of the Assignor's Group of research, development (including any studies or trials (whether or not undertaken with Third Parties)), or use of the Products and the Pipeline Compounds, and the Commercialisation of the Products, but excluding the Manufacturing of the Products, and in all cases other than the Assignor's Group Turkey Business and the Assignor's Group Retained Respiratory Business;

"Business IPR" means:

(i) all Patents owned by or licensed to any member of the Assignor's Group which relate to any Product, Relevant Compound or Pipeline Compound (including, all Patents owned by or licensed to any member of the Assignor's Group: (a) which relate to any formulation of, the Manufacture of or any method of use for any indication of, any Product, Relevant Compound or Pipeline Compound; or (b) which primarily relate to the combination of any Product, Relevant Compound or Pipeline Compound with any other active pharmaceutical ingredient; and

(ii) all Intellectual Property Rights (other than Patents) owned by or licensed to any member of the Assignor's Group which relate, primarily or exclusively to any Product, Relevant Compound or Pipeline Compound;

"Commercialise" means, with respect to a Product or a Pipeline Compound, to seek, obtain or maintain Product Approvals or Pipeline Compound Approvals, as applicable, import, export, license, outsource, advertise, promote, market, distribute, register or sell such Product or Pipeline Compound, as applicable, and **"Commercialising"** and **"Commercialisation"** shall be construed accordingly;

"Control" means the power to direct the management and policies of a Person (directly or indirectly), whether through ownership of voting securities, by contract or otherwise (and the term **"Controlled"** shall be interpreted accordingly);

"Co-Owned Business IPR" means the Patents relating to Alvesco or Zetonna that are co-owned by a member of the Assignor's Group and 3M, including the Patents listed in Part B of Schedule 3 to this Agreement;

"Court Order" means any order, decree, consent decree, writ, injunction, ruling, decision or judgment of any Governmental Entity that is binding on any Person or its property under Applicable Law;

"Governmental Entity" means any supra-national, federal, national, state, county, local, municipal or other governmental, regulatory or administrative authority, agency, commission or other instrumentality, any court, tribunal or arbitral body with competent jurisdiction, or any national securities exchange or automated quotation service including, any governmental regulatory authority or agency responsible for the grant approval, clearance, qualification, licensing or permitting of any aspect of the research, development, Manufacture, or Commercialisation of the Products and the Pipeline Compounds including the FDA, the European Medicines Agency, or any successor agency thereto;

"Intellectual Property Rights" means all intellectual property and proprietary rights of any kind or nature, whether protected, created or arising under any Applicable Law, including all: (i) rights in inventions; (ii) Patents; (iii) Trade Marks; (iv) rights in Know-how; (v) copyrights (including copyrights in software); (vi) Trade Secrets; (vii) rights in databases, rights in compilations of data (including personally identifiable information) and aggregated data; (viii) registered designs and unregistered design rights; (ix) rights in proprietary information and confidential information in any form, whether or not specially listed herein and all rights to limit the use or disclosure of such information; (x) registrations, grants and applications relating to any of the foregoing and all renewals, restorations and extensions thereof; (xi) similar or equivalent rights to any of the foregoing; and (xii) rights (including rights to bring actions for past, present or future infringement or misappropriation) and priorities afforded under any Applicable Law with respect to the foregoing;

"Invalidity Claim" has the meaning given to it in Clause 3.10.2;

"Know-how" means existing and available industrial and commercial information, know how, data and techniques in any form not in the public domain including drawings, specifications, processes and formulae, data (including all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, safety, preclinical and clinical data), reports, project reports and testing procedures, instruction and training manuals, tables of operating conditions, market forecasts, lists and particulars of customers and suppliers;

"Lead Party" means a Party that elects to take any action in relation to the enforcement or defence, as applicable, of the 3M Business IPR against any Third Party Infringement or Invalidity Claim in accordance with Clause 3.12 or Clause 3.13;

"Manufacture", "Manufacturing" or "Manufactured" means all activities related to the manufacture, planning, purchasing of materials for, production, processing, compounding, storage, filling, finishing, packaging, labelling, leafleting, shipping, warehousing (prior to distribution), quality control testing, waste disposal, quality release, sample retention and stability testing of products;

"Owned Business IPR" means the Business IPR which is owned or co-owned by any member of the Assignor's Group;

"Patents" means: all (i) issued patents and patent applications (including design patents, method of use patents, combination patents and any patents that issue as a result of any patent applications); (ii) renewals, restorations, re-issues, re-examinations or any patent granted as a result of any other post-grant proceedings, patent term extensions,

divisionals, continuations, continuations-in-part, revisions, supplementary protection certifications, utility models, and substitutions relating to any issued patents and patent applications; and (iii) rights and priorities afforded under any Applicable Law with respect to any of the foregoing;

"Person" means any person or entity, whether an individual, trustee, corporation, limited liability company, general partnership, limited partnership, trust, unincorporated organization, business association, firm, joint venture, executor, administrator or other legal personal representative, or any other legal entity, including a Governmental Entity;

"Pipeline Compounds" means the products in development set out in part B of schedule 1 of the Asset Purchase Agreement;

"Products" means the medicinal products set out in the first column of part A of schedule 1 of the Asset Purchase Agreement;

"Prosecution and Maintenance" means the preparation, filing, prosecution and maintenance of 3M Business IPR (but excluding, for the avoidance of doubt, the conduct and defence of any infringement, re-examinations, re-issues, interference proceedings, opposition, revocation, nullity, cancellation or other similar post-grant proceedings in relation to the 3M Business IPR);

"Relevant Compound" means roflumilast, ciclesonide or any metabolite, salt or pro-drug (including ester pro-drug form) of roflumilast or ciclesonide;

"Relevant Part" means with respect to any Co-Owned Business IPR, the rights, title and interests owned by any member of the Assignor's Group in such Co-Owned Business IPR;

"Solely-Owned 3M Business Patents" means the Patents relating to Alvesco or Zetonna that are owned solely by a member of the Assignor's Group and included within the B641 patent family, including those Patents that are listed in Part A of Schedule 3 to this Agreement;

"Third Party" means any Person or entity other than the Parties or their respective Affiliates and permitted successors and assigns;

"Third Party Infringement" has the meaning given to it in Clause 3.10.1;

"3M" means 3M Innovation Properties Company (or any of its Affiliates);

"3M Business IPR" means the Solely-Owned 3M Business Patents and the Co-Owned Business IPR;

"3M Transfer Date" means the date on which 3M consents to the assignment of the Relevant Part of the Co-Owned Business IPR from the Assignor to the Assignee;

"Trade Marks" means all (i) trade marks, service marks, rights in trade dress, rights in trade names, business names, logos, slogans and get-up, whether registered or unregistered, together with any registrations and applications for registration thereof and all extensions and renewals of any of the foregoing and all goodwill associated with or symbolized by any of the foregoing, (ii) URL and domain name registrations and rights in social media handles, and (iii) rights and priorities afforded under any Applicable Law with respect to the foregoing; and

"Trade Secrets" means information that derives independent economic value from not being generally known to, and not being readily ascertainable by proper means by other Persons who can obtain economic value from its disclosure or use.

1.2 Singular, plural, gender

References to one gender include all genders and references to the singular include the plural and vice versa.

1.3 References to persons and companies

References to:

- 1.3.1 a person include any company, partnership or unincorporated association (whether or not having separate legal personality); and
- 1.3.2 a company include any company, corporation or any body corporate, wherever incorporated.

1.4 Schedules etc.

References to this Agreement shall include any Schedules to it and references to Clauses and Schedules are to Clauses of, and Schedules to, this Agreement. References to paragraphs and Parts are to paragraphs and Parts of the Schedules.

1.5 Headings

Headings shall be ignored in interpreting this Agreement.

1.6 Legal terms

References to any English legal term shall, in respect of any jurisdiction other than England, be construed as references to the term or concept which most nearly corresponds to it in that jurisdiction.

1.7 Non-limiting effect of words

The words "including", "include", "in particular" and words of similar effect shall not be deemed to limit the general effect of the words that precede them.

2 Assignment

Pursuant to and for the consideration set out in the Asset Purchase Agreement, subject to Clause 3, the Assignor hereby assigns to the Assignee (and, in relation to the Assigned Designs owned or co-owned by another member of the Assignor's Group, shall procure that each other relevant member of the Assignor's Group shall assign to the Assignee) and the Assignee hereby accepts all of the Assignor's right, title, and interest in and to:

- (i) the Assigned IPR;
- (ii) the entitlement to (a) any registered Patents granted pursuant to any of the applications contained in the Assigned Patents; (b) co-ownership with 3M of any registered Patents granted pursuant to any of the applications contained in the Co-Owned Business IPR; and (c) any registered designs granted pursuant to any of the applications contained in the Assigned Designs; and
- (iii) the right to bring or defend proceedings and obtain relief (and to retain any damages and other monies recovered) in respect of any infringement or other

cause of action arising from ownership of any of the Assigned IPR, whether occurring on or after the date of this Agreement.

3 3M Business IPR

- 3.1** The effective date of the assignment of the 3M Business IPR from the Assignor to the Assignee under this Agreement shall be the 3M Transfer Date, or such other date between the date of this Agreement and the 3M Transfer Date as may be agreed by the Parties in writing prior to the 3M Transfer Date, and not the date of this Agreement.

Licence

- 3.2** The Assignor hereby grants, and shall procure that any other relevant members of the Assignor's Group shall grant, with effect from the date of this Agreement until such date as the 3M Business IPR is assigned to the Assignee, to the Assignee and each member of the Assignee's Group, an exclusive, irrevocable, fully paid-up, royalty-free and worldwide licence, with the ability to sub-license through multiple tiers (only to the extent permitted without Third Party Consent in relation to the Co-Owned Business IPR) to use (and perform all other acts which constitute infringement of) all 3M Business IPR.

Prosecution and Maintenance

- 3.3** Between the date of this Agreement and the date the 3M Business IPR is assigned to the Assignee and subject to the terms of the Assignor's (or any of its Affiliates') contractual arrangements with 3M in relation to the Co-Owned Business IPR, as between the Parties the Assignor shall, subject to Clause 3.7, conduct, and pay all fees and other expenses (including all official registry fees) relating to, the Prosecution and Maintenance of the 3M Business IPR.

- 3.4** The Assignor shall, from time to time upon the Assignee's reasonable request, provide the Assignee with an update on the status of the Prosecution and Maintenance of the 3M Business IPR.

- 3.5** Subject to the terms of the Assignor's (or any of its Affiliates') contractual arrangements with 3M in relation to the Co-Owned Business IPR, the Assignor shall:

- 3.5.1** promptly provide the Assignee with all information that the Assignor receives, whether from 3M or other sources, which relates to the Prosecution and Maintenance of the 3M Business IPR; and

- 3.5.2** consult in good faith with the Assignee prior to taking any steps (including communications with 3M) which relate to the Prosecution and Maintenance of the 3M Business IPR, and shall follow all reasonable instructions provided by the Assignee in relation thereto.

- 3.6** The Assignee shall co-operate fully with the Assignor in relation to the Prosecution and Maintenance of the 3M Business IPR and shall, at the Assignee's request and cost (including legal and professional costs and expenses), take all steps as may be reasonably required by the Assignor in relation to the Prosecution and Maintenance of the 3M Business IPR.

- 3.7** If the Assignor intends to withdraw, surrender, allow to lapse or otherwise cease the Prosecution and Maintenance of any of the Solely-Owned 3M Business Patents, it shall give the Assignee reasonable written notice of such intention (which notice shall be no less

than three months prior to the renewal date of any relevant Solely-Owned 3M Business Patents which are registered) (the "Assignor Abandonment Notice"). At the Assignee's written request (the "Assignee Abandonment Request"), the Assignor shall assign any Solely-Owned 3M Business Patents that are the subject of an Assignor Abandonment Notice to the Assignee at the Assignee's cost but for no or nominal consideration and otherwise on the terms that are substantially similar to the applicable terms of this Agreement. If the Assignee does not provide an Assignee Abandonment Request to the Assignor within the relevant reasonable period, the Assignor shall be entitled to withdraw, surrender, allow to lapse or otherwise cease the Prosecution and Maintenance of the relevant Solely-Owned 3M Business Patents.

- 3.8** Neither the Assignor nor any of its Affiliates shall be liable to the Assignee or any of its Affiliates, or any of their officers or employees, whether in contract, in tort (including negligence), under statute or otherwise, in connection with the Prosecution and Maintenance of the 3M Business IPR provided that the Assignor has (i) complied with its obligations under Clauses 3.4 to 3.5 and 3.7, and (ii) used reasonable care in conducting the Prosecution and Maintenance of the 3M Business IPR in accordance with Clause 3.3.

Enforcement:

- 3.9** The Parties acknowledge and agree that their respective rights and obligations under Clauses 3.10 to 3.18 shall, at all times, be subject to the terms of the Assignor's (or any of its Affiliates') contractual arrangements with 3M.

- 3.10** Between the date of this Agreement and the date the 3M Business IPR is assigned to the Assignee, each Party shall promptly notify the other Party in writing on becoming aware of:

- 3.10.1 any actual, threatened or suspected infringement or unauthorised use by any third party of any of the 3M Business IPR (including acts of passing off, acts of unfair competition or any similar causes of action) ("Third Party Infringement"); or
3.10.2 any actual or threatened claim by a third party challenging the validity, enforceability or ownership of any of the 3M Business IPR, before any relevant Intellectual Property Rights registry or any court ("Invalidity Claim").

- 3.11** The notice to be provided under Clause 3.10 shall include such information as the notifying Party has concerning:

- 3.11.1 the identity of the Person(s) involved in the Third Party Infringement or Invalidity Claim;
3.11.2 the details of the Third Party Infringement or Invalidity Claim; and
3.11.3 how the notifying Party was alerted to the Third Party Infringement or Invalidity Claim.

- 3.12** Subject to Clause 3.18, the Assignor shall, at the Assignor's cost (including legal and professional costs and expenses), have the first right to take whatever action it deems appropriate in its sole discretion in respect of any Third Party Infringement or Invalidity Claim (and to assume responsibility of any Third Party Infringement or Invalidity Claim which is on-going as at the date of this Agreement). This shall include, subject to Clause 3.18, the right to bring an action for a permanent or preliminary injunction or

institute, defend, settle or otherwise resolve any actions or proceedings relating to any Third Party Infringement or Invalidity Claim. The Assignor shall not have any obligation under this Clause 3.12 to take any action in relation to the enforcement or defence of the 3M Business IPR against any Third Party Infringement or Invalidity Claim.

3.13 If the Assignor:

- 3.13.1 does not take any action in accordance with Clause 3.12 to enforce or defend, as applicable, the 3M Business IPR against any Third Party Infringement or Invalidity Claim within 20 Business Days of being notified of such Third Party Infringement or Invalidity Claim (or such shorter period as the Assignee may reasonably request in order to preserve the right to: (a) obtain interim or preliminary relief for any Third Party Infringement; or (b) maintain any 3M Business IPR the subject of an Invalidity Claim); or
- 3.13.2 notifies the Assignee in writing that it does not wish to take any action under Clause 3.12,

the Assignee shall, subject to Clause 3.18, at the Assignee's cost (including legal and professional costs and expenses), have the right to take whatever action it deems appropriate in its sole discretion in respect of any such Third Party Infringement or Invalidity Claim (and any counterclaims).

3.14 The Assignee's rights under Clause 3.13 shall include, subject to Clause 3.18, the right to bring an action for a permanent or preliminary injunction or institute, defend, settle or otherwise resolve any actions or proceedings relating to any Third Party Infringement or Invalidity Claim. The Assignee shall not have any obligation under Clause 3.13 to take any action in relation to the enforcement or defence of the 3M Business IPR against any Third Party Infringement or Invalidity Claim.

3.15 Each Party shall co-operate fully with the Lead Party (where applicable) in relation to any Third Party Infringement or Invalidity Claim and shall, at the Lead Party's request and cost (including legal and professional costs and expenses), take all steps as may be reasonably required by the Lead Party in relation to any Third Party Infringement or Invalidity Claim, including by:

- 3.15.1 agreeing to legal proceedings being brought jointly in the names of the Assignor and the Assignee or to being joined as a party to legal proceedings; and
- 3.15.2 allowing the Lead Party to take such action in the name of and on behalf of the non-leading Party (or another member of its Group) as is reasonably necessary to enforce or defend, as applicable, the 3M Business IPR against any Third Party Infringement or Invalidity Claim in accordance with this Agreement, provided that the Lead Party shall, in the course of continuing such action, take into account and have due regard to, and not take any action which would materially damage, the reputation of any member of the non-leading Party or any of its Affiliates or any of their respective directors, officers, employees or agents.

3.16 The Lead Party shall keep the non-leading Party reasonably informed of the status of any action it elects to take in relation to the enforcement or defence, as applicable, of the 3M Business IPR against any Third Party Infringement or Invalidity Claim in accordance with this Agreement.

- 3.17 The Lead Party shall be entitled to any and all damages, accounts of profit, awards of costs obtained from any actions taken by the Lead Party pursuant to this Agreement.
- 3.18 Neither Party may make any statement of admission, or enter into any compromise, settlement or agreement (including by way of agreeing to the amendment of any 3M Business IPR) with any Person in relation to any Third Party Infringement or Invalidity Claim, which:
- 3.18.1 is reasonably likely to compromise the enforceability or validity of the 3M Business IPR, without the prior written consent of the other Party (such consent not to be unreasonable withheld, conditioned or delayed); or
 - 3.18.2 requires the other Party to make any payment.

4 Further assurance

- 4.1 Without prejudice to clause 6.8 of the Asset Purchase Agreement or the services to be provided in relation to the transfer of the Assigned IPR under the Transitional Services Agreement, at any time after the date of this Agreement, at the reasonable request of the Assignee, the Assignor shall, execute such documents and do such acts as the Assignee may reasonably require under the law of any country for the purpose of giving to the Assignee the full benefit of all the provisions of this Agreement. To the extent to which such assistance falls within the scope of the services to be provided under the Transitional Services Agreement, the Assignee shall pay for such assistance in accordance with the Transitional Services Agreement. To the extent to which such assistance does not fall within the scope of the services to be provided under the Transitional Services Agreement, such assistance shall be at the expense of the Assignee save that the Assignor shall bear its own internal costs.

5 Whole agreement

- 5.1 This Agreement, the Transitional Services Agreement and the Asset Purchase Agreement contain the whole agreement between the parties relating to the subject matter of this Agreement at the date of this Agreement to the exclusion of any terms implied by law which may be excluded by contract, and supersedes any previous written or oral agreement between the parties in relation to the matters dealt with in this Agreement.
- 5.2 The Assignee acknowledges that it has not been induced to enter this Agreement by any representation, warranty or undertaking not expressly incorporated into it or the Asset Purchase Agreement.
- 5.3 In the event of any inconsistency between the terms of this Agreement and the terms of the Asset Purchase Agreement, the terms of the Asset Purchase Agreement shall prevail provided that, for the avoidance of doubt, the Parties agree that Clause 4 (Further Assurances) of this Agreement shall prevail over clause 16.1 (Further assurances) of the Asset Purchase Agreement in the event of any inconsistency.

6 Counterparts

This Agreement may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument. Either Party may enter into this Agreement by executing any such counterpart.

7 Governing law and submission to jurisdiction

- 7.1 This Agreement and any non-contractual obligations arising out of or in connection with it shall be governed by English law.
- 7.2 Each Party irrevocably agrees that the courts of England are to have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Agreement and that accordingly any proceedings arising out of or in connection with this Agreement shall be brought in such courts. Each Party irrevocably submits to the jurisdiction of such courts and waives any objection to proceedings in any such court on the ground of venue or on the ground that the proceedings have been brought in an inconvenient forum.

In witness whereof this Agreement has been duly executed.

SIGNED by

Jerelyn Trockenbem

for and on behalf of
TAKEDA GMBH

} *George T. F.*

SIGNED by

ANDREA FERRARI

for and on behalf of
TAKEDA GMBH

SIGNED by

for and on behalf of
ASTRAZENECA AB (PUBL)

1

In witness whereof this Agreement has been duly executed.

SIGNED by

for and on behalf of
TAKEDA GMBH

}

SIGNED by

for and on behalf of
TAKEDA GMBH

}

SIGNED by

for and on behalf of
ASTRAZENECA AB (PUBL)

JAN LOFTRIKE, PRESIDENT



}

Schedule 1

Assigned Patents

...

...

...

Schedule 2
Assigned Registered Designs

Schedule 3

3M Business IPR

Part A:Solely Owned 3M Business Patents

Part B: Co-Owned Business IPR

Project Daisy – Intellectual Property Rights Assignment (Patents and Designs)

Schedule 1

Assigned Patents

Ciclesonide Patents

Invention:	1009	Title:	R-Ciclesonide-Metabolite Synthesis from Desonide	Status as of:	4-Dec-15	Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH
<hr/>							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
AT	EPC	01	01990391.3-1211	6-Nov-01	1335929	25-Aug-10	6-Nov-21
AU	PCT	01	2002229536	6-Nov-01	2002229536	2-Aug-07	6-Nov-21
BE	EPC	01	01990391.3-1211	6-Nov-01	1335929	25-Aug-10	6-Nov-21
BR	PCT	01	PI0115220-3	6-Nov-01			6-Nov-21
BY	EAC	01	200300504	6-Nov-01	006231	27-Oct-05	6-Nov-21
CA	PCT	01	2430196	6-Nov-01	2430196	26-Jan-10	6-Nov-21
CH	EPC	01	01990391.3-1211	6-Nov-01	1335929	25-Aug-10	6-Nov-21
CN	PCT	01	01818551.7	6-Nov-01	ZL01818551.7	19-Jul-06	6-Nov-21
CZ	PCT	01	PV2003-1272	6-Nov-01	303885	2-May-13	6-Nov-21
DE	ORD	01	10055820.8-43	10-Nov-00	10055820	25-Jul-02	10-Nov-20
DE	EPC	01	01990391.3-1211	6-Nov-01	60142920.6-08	25-Aug-10	6-Nov-21
EA	PCT	01	200300504	6-Nov-01	006231	27-Oct-05	6-Nov-21
EP	PCT	01	01990391.3-1211	6-Nov-01	1335929	25-Aug-10	6-Nov-21

Invention:	1009							
Title:	R-Ciclesonide Metabolite Synthesis from Desomide							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
ES	EPC	01	01990391.3-1211	6-Nov-01	1335929	25-Aug-10	6-Nov-21	Granted
FR	EPC	01	01990391.3-1211	6-Nov-01	1335929	25-Aug-10	6-Nov-21	Granted
GB	EPC	01	01990391.3-1211	6-Nov-01	1335929	25-Aug-10	6-Nov-21	Granted
HK	REG	01	04100855.0	6-Nov-01	1058043B	13-May-11	6-Nov-21	Granted
HU	PCT	01	P03022/20	6-Nov-01	228432	27-Feb-13	6-Nov-21	Granted
IL	PCT	01	155274	6-Nov-01	155274	1-Feb-11	6-Nov-21	Granted
IN	PCT	01	2003/00387/MUM	6-Nov-01	208833	13-Aug-07	6-Nov-21	Granted
IT	EPC	01	01990391.3-1211	6-Nov-01	1335929	25-Aug-10	6-Nov-21	Granted
JP	PCT	01	2002-541116	6-Nov-01	4456811	12-Feb-10	6-Nov-21	Granted
KR	PCT	01	10-2003-7006292	6-Nov-01	10-0809510	26-Feb-08	6-Nov-21	Granted
MX	PCT	01	PA/A/2003/0044123	6-Nov-01	248509	29-Aug-07	6-Nov-21	Granted
NL	EPC	01	01990391.3-1211	6-Nov-01	1335929	25-Aug-10	6-Nov-21	Granted
NO	PCT	01	20031964	6-Nov-01	325286	17-Mar-08	6-Nov-21	Granted
NZ	PCT	01	525707	6-Nov-01	525707	10-Mar-05	6-Nov-21	Granted
PL	PCT	01	P361616	6-Nov-01	205674	19-Jul-10	6-Nov-21	Granted
RU	EAC	01	200300504	6-Nov-01	006231	27-Oct-05	6-Nov-21	Granted
SK	PCT	01	PP0555-2003	6-Nov-01	287545	22-Nov-10	6-Nov-21	Granted
US	PCT	01	10/399889	6-Nov-01	7468433	23-Dec-08	17-Feb-24	Granted
WO	ORD	01	PCT/EPO/112808	6-Nov-01			6-Nov-21	National Phase
								APAG

Invention:	1009					
Title:	R-Ciclesonide-Metabolite Synthesis from Desonide					
Status as of:	4-Dec-15					
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH					
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date
ZA	PCT	01	2003/3121	6-Nov-01	2003/3121	30-Jun-04
					Expiry Date	Status
					6-Nov-21	Granted
					Owner/Co- Owner	Owner/Co- Owner
					TAKDE	

3

Invention:	1078							
Title:	Hypotonic Suspension with Ciclosporine for Application to Mucosa							
Status as of:	25-Feb-2016							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AL	EPE	01	AL/P/05/01427	20-Oct-00	01427	29-Dec-04	20-Oct-20	Granted
AT	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
AU	PCT	01	79531/00	20-Oct-00	781895	13-Oct-05	20-Oct-20	Granted
BA	PCT	01	BAP021040A	20-Oct-00	BAP021040	27-May-11	20-Oct-20	Examination
BE	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
BG	PCT	01	106512	20-Oct-00	65818	09-Mar-10	20-Oct-20	Granted
BR	PCT	01	P/0014878-4	20-Oct-00	P/0014878-4	11-Aug-15	11-Aug-25	Granted
BY	EAC	01	200200375	20-Oct-00	008015	25-Aug-05	20-Oct-20	Granted
CA	PCT	01	2388322	20-Oct-00	2388322	18-Sep-07	20-Oct-20	Granted
CH	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
CL	ORD	01	2000-2884	19-Oct-00	44.007	23-Oct-08	23-Oct-23	Granted
CN	DIV	01	201010223433.5	20-Oct-00	ZL201010223433	10-Oct-12	20-Oct-20	Granted
CN	PCT	01	00814405.2	20-Oct-00	ZL00814405.2	29-Oct-14	20-Oct-20	Granted
CO	ORD	01	00079610	19-Oct-00	28593	21-Nov-06	19-Oct-20	Granted
CY	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
CZ	PCT	01	PV2002-1238	20-Oct-00	297779	16-Feb-07	20-Oct-20	Granted
DE	EPC	01	00969966.1	20-Oct-00	60017175.2-08	29-Dec-04	20-Oct-20	Granted
DK	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
EA	PCT	01	200200375	20-Oct-00	008015	25-Aug-05	20-Oct-20	National Phase
EP	PCT	01	00969966.1-2123	20-Oct-00	1225902	29-Dec-04	20-Oct-20	EP
								APAG

Invention:	1078							
Title:	Hypotonic Suspension with Ciclosporine for Application to Mucosa							
Status as of:	25-Feb-2016							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
ES	EPC	01	009639366.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
FI	EPC	01	009639366.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
FR	EPC	01	009639366.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
GB	EPC	01	009639366.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
GR	EPC	01	009639366.1	20-Oct-00	3052607	29-Dec-04	20-Oct-20	Granted
HK	REG	01	03103180.1	20-Oct-00			20-Oct-20	Published
HK	REG	02	111040819	20-Oct-00	11149719B	12-Jul-13	20-Oct-20	Granted
HR	PCT	01	P20020346A	20-Oct-00	P20020346	10-Jun-11	20-Oct-20	Granted
HU	PCT	01	P0203339	20-Oct-00	228893	22-May-13	20-Oct-20	Granted
ID	PCT	01	W-2002.00891	20-Oct-00	1D0016635	16-Dec-05	20-Oct-20	Granted
IE	EPC	01	009639366.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
IL	PCT	01	148691	20-Oct-00	148691	11-Mar-07	20-Oct-20	Granted
IN	PCT	01	2002/00308/MUM	20-Oct-00	251589	26-Mar-12	20-Oct-20	Granted
IT	EPC	01	009639366.1	20-Oct-00	50200590129516 3	29-Dec-04	20-Oct-20	Granted
JP	PCT	01	2001-531392	20-Oct-00	4264211	20-Feb-09	20-Oct-20	Granted
KR	PCT	01	10-2002-7004995	20-Oct-00	10-0722209	21-May-07	20-Oct-20	Granted
KR	PTE	01	10-2009-0035134	22-Apr-09	10-0722209	21-Oct-20	16-May-21	Granted
KS	REG	01	592	20-Oct-00	263	17-Jan-12	20-Oct-20	Granted
LT	EPE	01	009639366.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted

Invention:	1078							
Title:	Hypotonic Suspension with Ciclosporine for Application to Mucosa							
Status as of:	25-Feb-2016							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
LU	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
LV	EPE	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
MC	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
ME	REG	01	P-856/08	20-Oct-00	005867	20-Dec-11	20-Oct-20	Granted
MK	EPE	01	00969966.1	20-Oct-00	901896	29-Dec-04	20-Oct-20	Granted
MX	PCT	01	PA/A/2002/003974	20-Oct-00	226172	08-Feb-05	20-Oct-20	Granted
MY	ORD	01	P120004915	19-Oct-00	MY-136987-A	31-Dec-08	31-Dec-23	Granted
NL	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
NO	PCT	01	20021898	20-Oct-00	327444	29-Jun-09	20-Oct-20	Granted
NZ	PCT	01	518298	20-Oct-00	518298	09-Mar-04	20-Oct-20	Granted
PE	ORD	01	1121.2000	19-Oct-00	4094	23-Aug-05	19-Oct-20	Granted
PH	ORD	01	1-2000-02890	23-Oct-00	1-2000-02890	02-Dec-05	23-Oct-20	Granted
PK	ORD	01	961/2000	18-Oct-00	137462	18-Feb-03	20-Oct-19	Granted
PL	PCT	01	P356191	20-Oct-00	199702	28-Mar-08	20-Oct-20	Granted
PT	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
RO	EPE	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
RS	PCT	01	P-280/02	20-Oct-00	50310	09-Jun-09	20-Oct-20	Granted
RU	EAC	01	200200375	20-Oct-00	006015	25-Aug-05	20-Oct-20	Granted
SE	EPC	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
SG	PCT	01	200201856-2	20-Oct-00	88137	30-Apr-04	20-Oct-20	Granted

Invention:	1078							
Title:	Hypotonic Suspension with Ciclesonide for Application to Mucosa							
Status as of:	25-Feb-2016							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomborg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
SI	EPE	01	00969966.1	20-Oct-00	1225902	29-Dec-04	20-Oct-20	Granted
SK	PCT	01	PP0692-2002	20-Oct-00	286196	11-Mar-08	20-Oct-20	Granted
TH	ORD	01	061178	17-Oct-00			17-Oct-20	Examination
TR	PCT	01	2002/00841	20-Oct-00	TR2002/00841	21-Oct-05	20-Oct-20	Granted
TW	ORD	01	89121994	19-Oct-00	I225788	01-Jan-05	19-Oct-20	Granted
TW	PTE	01		21-Sep-10		20-Oct-20		Pending
US	PCT	01	10/110629	20-Oct-00	6767901	27-Jul-04	21-Oct-20	Granted
WO	ORD	01	PCT/JP00/07350	20-Oct-00		20-Oct-20	National Phase	BYK
ZA	PCT	01	2002/3077	20-Oct-00	2002/3077	26-Feb-03	20-Oct-20	Granted

11

Invention:	1081							
Title:	Ciclesonide Suspension using HPMC as a Wetting Agent							
Status as of:	25-Feb-2016							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AL	EPE	01	AL/P04/01241	20-Oct-00	01241	30-Jun-04	20-Oct-20	Granted
AT	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
AU	PCT	01	79532/00	20-Oct-00	776587	13-Jan-05	20-Oct-20	Granted
AU	PTE	01	79532/00	30-Mar-12	776587	21-Oct-20	20-Oct-25	Granted
BA	PCT	01	BAP021046A	20-Oct-00	BAP021046	27-May-11	20-Oct-20	Granted
BE	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
BG	PCT	01	106517	20-Oct-00	65799	21-Jan-10	20-Oct-20	Granted
BR	PCT	01	P10014880-6	20-Oct-00	P10014880-6	11-Aug-15	11-Aug-25	Granted
BY	EAC	01	200200383	20-Oct-00	005201	30-Dec-04	20-Oct-20	Granted
CA	PCT	01	2388325	20-Oct-00	2388325	18-Sep-07	20-Oct-20	Granted
CH	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
CL	ORD	01	2000-2853	18-Oct-00	45937	25-Nov-09	25-Nov-24	Granted
CN	PCT	01	00814253-X	20-Oct-00	ZL00814253-X	27-Apr-05	20-Oct-20	Granted
CO	ORD	01	00079609	19-Oct-00	28594	27-Apr-06	19-Oct-20	Granted
CY	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
CZ	PCT	01	PV2002-1284	20-Oct-00	297780	16-Feb-07	20-Oct-20	Granted
DE	EPC	01	00969967.9-2123	20-Oct-00	60011924.6-08	30-Jun-04	20-Oct-20	Granted
DK	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
EA	PCT	01	200200383	20-Oct-00	005201	30-Dec-04	20-Oct-20	National Phase
EP	PCT	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	EP
								NoOpposition

Invention:	1081							
Title:	Ciclesonide Suspension using HPMC as a Wetting Agent							
Status as of:	25-Feb-2016							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
ES	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
FI	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
FR	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
GB	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
GR	EPC	01	00969967.9-2123	20-Oct-00	3050657	30-Jun-04	20-Oct-20	Granted
HK	REG	01	03103221.2	20-Oct-00	1051003B	23-Dec-05	20-Oct-20	Granted
HR	PCT	01	P20020345A	20-Oct-00	P20020345	05-Dec-06	20-Oct-20	Granted
HU	PCT	01	P0203756	20-Oct-00	228894	22-May-13	20-Oct-20	Granted
ID	PCT	01	W00-2002.00892	20-Oct-00	1D0014700	22-Nov-04	20-Oct-20	Granted
IE	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
IL	PCT	01	148725	20-Oct-00	148725	01-Apr-07	20-Oct-20	Granted
IN	PCT	01	2002/00319/MLIM	20-Oct-00	213266	26-Dec-07	20-Oct-20	Granted
IT	EPC	01	00969967.9-2123	20-Oct-00	50200490124392	30-Jun-04	20-Oct-20	Granted
JP	PCT	01	2001-531393	20-Oct-00	4	04-Nov-11	20-Oct-20	Granted
KR	PCT	01	10-2002-7004994	20-Oct-00	10-0705372	03-Apr-07	20-Oct-20	Granted
KS	REG	01	593	20-Oct-00	235	12-Jan-12	20-Oct-20	Granted
LT	EPE	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
LU	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
LV	EPE	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
MC	EPC	01	00969967.9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted

Invention:	1081							
Title:	Ciclesonide Suspension using HPMC as a Wetting Agent							
Status as of:	25-Feb-2016							
Owner:	APAG = ALTANA Pharma AG, BYK = BYK Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
ME	REG	01	P-857/08	20-Oct-00	00568	20-Dec-11	20-Oct-20	Granted
MK	EPE	01	00969967 9-2123	20-Oct-00	901589	30-Jun-04	20-Oct-20	Granted
MX	PCT	01	PA/A/2002/003975	20-Oct-00	224416	23-Nov-04	20-Oct-20	Granted
MY	ORD	01	PI200004916	19-Oct-00	MY-121175-A	30-Dec-05	30-Dec-20	Granted
NL	EPC	01	00969967 9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
NO	PCT	01	20021866	20-Oct-00	321379	22-Jun-09	20-Oct-20	Granted
NZ	PCT	01	518299	20-Oct-00	518299	05-Jul-04	20-Oct-20	Granted
PE	ORD	01	11192000	19-Oct-00	3217	23-Sep-03	19-Oct-20	Granted
PH	ORD	01	1-2000-0002891	23-Oct-00	1-2000-0002891	03-Sep-07	23-Oct-20	Granted
PK	ORD	01	960/2000	18-Oct-00	137477	18-Feb-03	20-Oct-19	Granted
PL	PCT	01	P356190	20-Oct-00	197537	12-Sep-07	20-Oct-20	Granted
PT	EPC	01	00969967 9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
RO	EPE	01	00969967 9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
RS	PCT	01	P-281/02	20-Oct-00	50345	07-Jul-09	20-Oct-20	Granted
RU	EAC	01	200200383	20-Oct-00	005201	30-Dec-04	20-Oct-20	Granted
SE	EPC	01	00969967 9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
SG	PCT	01	200201625-1	20-Oct-00	81979	30-Apr-04	20-Oct-20	Granted
SI	EPE	01	00969967 9-2123	20-Oct-00	1227817	30-Jun-04	20-Oct-20	Granted
SK	PCT	01	PP0693-2002	20-Oct-00	286194	11-Mar-08	20-Oct-20	Granted
TH	ORD	01	061179	17-Oct-00		17-Oct-20	Examination	TAKDE

Invention:	1081							
Title:	Ciclesonide Suspension using HPMC as a Wetting Agent							
Status as of:	25-Feb-2016							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomborg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
TR	PCT	01	2002/00831	20-Oct-00	TR2002/00831	21-Oct-05	20-Oct-20	Granted
TW	ORD	01	89121991	19-Oct-00	I269655	01-Jan-07	19-Oct-20	Granted
US	PCT	01	10/110632	20-Oct-00	8383611	26-Feb-13	20-Oct-20	Granted
US	CON	01	13/688659	20-Oct-00			20-Oct-20	Appealed
WO	ORD	01	PCT/JP00/07351	20-Oct-00			20-Oct-20	National Phase
ZA	PCT	01	2002/3078	20-Oct-00	2002/3078	29-Jan-03	20-Oct-20	Granted

II

Invention:	1112							
Title:	Process for Production of Ciclosporide with Defined Particle Size							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG; NYCO = Nycomed GmbH; TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
AT	EPC	01	04723609.6-2117	26-Mar-04	E546459	22-Feb-12	26-Mar-24	Granted
AU	PCT	01	2004224092	26-Mar-04	2004224092	18-Jun-10	26-Mar-24	Granted
BA	PCT	01	BAP062322A	26-Mar-04	BAP062322	09-Jul-10	26-Mar-24	Granted
BE	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
BG	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
BR	PCT	01	P10408569-8	26-Mar-04			26-Mar-24	Examination
BY	EAC	01	200501391	26-Mar-04	0111157	27-Feb-09	26-Mar-24	Granted
CA	PCT	01	2519752	26-Mar-04	2519752	29-May-12	26-Mar-24	Granted
CH	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
CL	ORD	01	636/2004	25-Mar-04				Pending
CN	PCT	01	200480007481.3	26-Mar-04	200480007481.3	23-Jul-08	26-Mar-24	Granted
CY	EPC	01	CY20121100425	26-Mar-04	CY1112970	22-Feb-12	26-Mar-24	Granted
CZ	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
DE	EPC	01	04723609.6-2117	26-Mar-04	602004036591.2	22-Feb-12	26-Mar-24	Granted
DK	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
EA	PCT	01	200501391	26-Mar-04	0111157	27-Feb-09	26-Mar-24	National Phase
EE	EPC	01	04723609.6-2117	26-Mar-04	E006759	22-Feb-12	26-Mar-24	Granted
EP	PCT	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	EP NoOpposition
ES	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted

Invention:	1112							
Title:	Process for Production of Ciclesamide with Defined Particle Size							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
FI	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
FR	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
GB	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
GC	ORD	01	GCCP/2004/3326	24-Mar-04				TAKDE
GR	EPC	01	04723609.6-2117	26-Mar-04	3077664	22-Feb-12	26-Mar-24	Granted
HK	REG	01	06109236.9	26-Mar-04	1088905B	03-Jul-09	26-Mar-24	Granted
HR	PCT	01	P20050917A	26-Mar-04	P20050917	30-Jan-14	26-Mar-24	Granted
HU	EPC	01	04723609.6-2117	26-Mar-04	E 013877	22-Feb-12	26-Mar-24	Granted
ID	PCT	01	W00-2005 02623	26-Mar-04	IDP0027612	18-Feb-11	26-Mar-24	Granted
IE	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
IL	PCT	01	170746	26-Mar-04	170746	29-Sep-12	26-Mar-24	Granted
IN	PCT	01	2005/01158/MUMNP	26-Mar-04	220902	10-Jun-08	26-Mar-24	Granted
IT	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
JP	PCT	01	2006-505496	26-Mar-04	4746535	20-May-11	26-Mar-24	Granted
KR	PCT	01	10-2005-707580	26-Mar-04	10-1102709	28-Dec-11	26-Mar-24	Granted
LB	ORD	01	1318	08-Mar-04	6943	13-Jul-04	08-Mar-24	Granted
LU	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
MC	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
MX	PCT	01	PA/A/2005/010041	26-Mar-04	286299	24-Apr-09	26-Mar-24	Granted
MY	ORD	01	P120040475	13-Feb-04	MY-143936-A	29-Jul-11	13-Feb-24	Granted

11

Invention:	1112							
Title:	Process for Production of Ciclesonide with Defined Particle Size							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
NL	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
NO	PCT	01	20054835	26-Mar-04	331984	21-May-12	26-Mar-24	Granted
NZ	PCT	01	542827	26-Mar-04	542827	12-Jun-08	26-Mar-24	Granted
PK	ORD	01	212/2004	25-Mar-04	138871	08-Apr-06	27-Mar-23	Granted
PL	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
PT	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
RO	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
RS	PCT	01	P-2005/0704	26-Mar-04	525459	10-Jan-13	26-Mar-24	Granted
RU	EAC	01	200501391	26-Mar-04	011157	27-Feb-09	26-Mar-24	Granted
SE	EPC	01	04723609.6-2117	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
SI	EPC	01	P200431866	26-Mar-04	1611150	22-Feb-12	26-Mar-24	Granted
SK	EPC	01	04723609.6-2117	26-Mar-04	E11828	22-Feb-12	26-Mar-24	Granted
TH	ORD	01	0401000574	20-Feb-04		20-Feb-24	Examination	APAG
TR	EPC	01	04723609.6-2117	26-Mar-04	TR2012/05596	22-Feb-12	26-Mar-24	Granted
TW	ORD	01	093104/36	19-Feb-04	1328589	11-Aug-10	19-Feb-24	Granted
US	PCT	01	10/549631	26-Mar-04		26-Mar-24	Published	TAKDE
VE	ORD	01	458-04	26-Mar-04		26-Mar-24	Examination	NYCO
WO	ORD	01	PCT/EP2004/05037 3	26-Mar-04		26-Mar-24	National Phase	APAG
ZA	PCT	01	2005/06943	26-Mar-04	2005/06943	26-Jul-06	26-Mar-24	Granted
								TAKDE

Invention:	1124							
Title:	Combination Ciclesonide with Antihistamine							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AT	EPC	01	0375551.3-2123	29-Aug-03	E472329	30-Jun-10	29-Aug-23	Granted
AT	EPC	11	10167527.0-2123	29-Aug-03	E572674	29-Aug-12	29-Aug-23	Granted
AU	PCT	01	2003273396	29-Aug-03	2003273396	26-Mar-09	29-Aug-23	Granted
BE	EPC	11	10167527.0-2123	29-Aug-03	2295062	29-Aug-12	29-Aug-23	Granted
BE	EPC	01	0375551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
BG	EPC	01	0375551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
BR	PCT	01	PI0313611-6	29-Aug-03			29-Aug-23	Published
CA	PCT	01	2495830	29-Aug-03	2495830	21-Aug-12	29-Aug-23	Granted
CH	EPC	11	10167527.0-2123	29-Aug-03	2295062	29-Aug-12	29-Aug-23	Granted
CH	EPC	01	0375551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
CZ	EPC	01	0375551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
DE	EPC	01	0375551.3-2123	29-Aug-03	60333205.6-08	30-Jun-10	29-Aug-23	Granted
DE	EPC	11	10167527.0-2123	29-Aug-03	60341989.5	29-Aug-12	29-Aug-23	Granted
DK	EPC	01	0375551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
EP	DIV	11	10167527.0-2123	29-Aug-03	2295062	29-Aug-12	29-Aug-23	EP
EP	PCT	01	0375551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	NoOpposition
ES	EPC	01	0375551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	EP
ES	EPC	11	10167527.0-2123	29-Aug-03	2295062	29-Aug-12	29-Aug-23	Granted
FR	EPC	11	10167527.0-2123	29-Aug-03	2295062	29-Aug-12	29-Aug-23	Granted

Invention:	1124							
Title:	Combination Ciclesonide with Antihistamine							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Case Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
FR	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
GB	EPC	11	10167527.0-2123	29-Aug-03	22950062	29-Aug-12	29-Aug-23	Granted
GB	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
GR	EPC	01	03755551.3-2123	29-Aug-03	3072846	30-Jul-10	30-Aug-23	Granted
HU	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
IL	PCT	01	168483	29-Aug-03	166483	1-Mar-14	29-Aug-23	Granted
IN	PCT	01	2005/00097/MUMNP	29-Aug-03	218635	4-Apr-08	28-Aug-23	Oppo Maint
IT	EPC	11	10167527.0-2123	29-Aug-03	22950062	29-Aug-12	29-Aug-23	Granted
IT	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	28-Aug-23	Granted
JP	PCT	01	2004-532150	29-Aug-03	4746318	20-May-11	29-Aug-23	Granted
KR	PCT	01	10-2005-7002903	29-Aug-03	10-1067795	20-Sep-11	29-Aug-23	Granted
MX	PCT	01	PA/A/2005/001885	29-Aug-03	276018	19-May-10	29-Aug-23	Granted
NL	EPC	11	10167527.0-2123	29-Aug-03	22950062	29-Aug-12	29-Aug-23	Granted
NL	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
NO	PCT	01	20051521	29-Aug-03	335400	8-Dec-14	29-Aug-23	Granted
NZ	PCT	01	538954	29-Aug-03	538954	9-Aug-07	29-Aug-23	Granted
PT	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
RO	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
SE	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted
SI	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted

Invention:	1124										
Title:	Combination Ciclosporine with Antihistamine										
Status as of:	4-Dec-15										
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH										
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status	Owner	Co-Owner	
SK	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted	TAKDE		
TR	EPC	01	03755551.3-2123	29-Aug-03	1545548	30-Jun-10	29-Aug-23	Granted	TAKDE		
TR	EPC	11	10167527.0-2123	29-Aug-03	2012/13214	29-Aug-12	29-Aug-23	Granted	TAKDE		
US	PCT	01	10/524821	29-Aug-03	7879832	1-Feb-11	4-Dec-25	Granted	TAKDE		
US	CON	01	12/973414	29-Aug-03	8486923	16-Jul-13	20-Sep-23	Granted	TAKDE		
WO	ORD	01	PCT/EP2003/009622	29-Aug-03			29-Aug-23	National Phase	APAG		
ZA	PCT	01	2005/0719	29-Aug-03	2005/0719	22-Feb-06	29-Aug-23	Granted	TAKDE		

Invention:	1156							
Title:	Combination Ciclesonide with R,R-Formoterol							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AT	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
AU	PCT	01	2003293833	11-Dec-03	2003293833	14-Jan-10	11-Dec-23	Granted
BA	PCT	01	BAP052230A	11-Dec-03	BAP052230	14-Dec-09	11-Dec-23	Granted
BE	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
CA	PCT	01	2508692	11-Dec-03	2508692	03-Apr-12	11-Dec-23	Granted
CH	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
DE	EPC	01	03789217.1-2123	11-Dec-03	60323138.1-08	20-Aug-08	11-Dec-23	Granted
DK	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
EP	PCT	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	EP
ES	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	NoOpposition
FR	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
GB	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
HR	PCT	01	P20050611A	11-Dec-03	P20050611	20-Dec-13	11-Dec-23	Granted
IS	PCT	01	7910	11-Dec-03	2597	15-Mar-10	11-Dec-23	Granted
IT	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
JP	PCT	01	2005-502319	11-Dec-03	4755495	03-Jun-11	11-Dec-23	Granted
NL	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
PT	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
RS	PCT	01	P-2005/0429	11-Dec-03	51707	01-Nov-11	11-Dec-23	Granted
SE	EPC	01	03789217.1-2123	11-Dec-03	1572217	20-Aug-08	11-Dec-23	Granted
								NYCO

Invention:	1158								
Title:	Combination Ciclosonide with R,R-Formoterol								
Status as of:	4-Dec-15								
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH								
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-Owner
US	CON	01	12/973350	11-Dec-03	8258124	04-Sep-12	11-Dec-23	Granted	TAKDE
US	PCT	01	10/537366	11-Dec-03	7879833	01-Feb-11	01-May-25	Granted	TAKDE
WO	ORD	01	PCT/EP2003/014045	11-Dec-03			11-Dec-23	National Phase	APAG

Invention:	1170							
Title:	Sterile Aqueous Composition containing Ciclosporide							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
AU	PCT	01	2003245043	2-Jul-03	2003245043	14-May-09	2-Jul-23	Granted
BR	PCT	01	PI03123774	2-Jul-03			2-Jul-23	Examination
BY	EAC	01	200500123	2-Jul-03	009843	28-Apr-08	2-Jul-23	Granted
CA	PCT	01	2491724	2-Jul-03	2491724	2-Apr-13	2-Jul-23	Granted
CN	PCT	01	038156105	2-Jul-03	ZL038156105	6-Feb-08	2-Jul-23	Granted
EA	PCT	01	200500123	2-Jul-03	009843	28-Apr-08	2-Jul-23	National Phase
EP	PCT	01	037386372-1455	2-Jul-03	1080365B	28-Nov-08	2-Jul-23	Appealed
HK	REG	01	061002153	2-Jul-03			2-Jul-23	Granted
HR	PCT	01	P200500062A	2-Jul-03	P200500062	21-Oct-13	2-Jul-23	Granted
ID	PCT	01	W00-2004.02985	2-Jul-03			2-Jul-23	Examination
IL	PCT	01	165666	2-Jul-03	165666	30-Jul-10	2-Jul-23	Granted
IN	PCT	01	2004/00703/MUMNP	2-Jul-03	225295	6-Nov-08	2-Jul-23	Granted
JP	PCT	01	2004-519234	2-Jul-03	4559221	30-Jul-10	2-Jul-23	Granted
KR	PCT	01	10-2004-7021677	2-Jul-03	10-1020687	2-Mar-11	2-Jul-23	Granted
MX	PCT	01	PA/A/2004/012756	2-Jul-03	273301	12-Jan-10	2-Jul-23	Granted
NO	PCT	01	20050529	2-Jul-03	335022	25-Aug-14	2-Jul-23	Granted
NZ	PCT	01	537945	2-Jul-03	537945	13-Dec-07	2-Jul-23	Granted
PL	PCT	01	P372940	2-Jul-03			2-Jul-23	Published
RS	PCT	01	P-04-1134	2-Jul-03			2-Jul-23	Published
RU	EAC	01	200500123	2-Jul-03	009843	28-Apr-08	2-Jul-23	Granted

Inventor:	1170								
Title:	Sterile Aqueous Composition containing Ciclolesonide								
Status as of:	4-Dec-15								
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH								
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-owner
US	DIV	01	12/461647	2-Jul-03	8268240	18-Sep-12	2-Oct-24	Granted	TAKDE
US	PCT	01	10/519484	2-Jul-03	8182824	22-May-12	6-Apr-25	Granted	TAKDE
WO	ORD	01	PCT/JP2003/008410	2-Jul-03			2-Jul-23	National Phase	APAG
ZA	PCT	01	2004/10377	2-Jul-03			2-Jul-23	Granted	TAKDE

Invention:	1182							
Title:	Dosage Forms for Ciclosporide for the Treatment of IBD							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AT	EPC	01	04766789.4-2107	15-Sep-04	1670481	4-Aug-10	15-Sep-24	Granted
AU	PCT	01	2004271743	15-Sep-04	2004271743	23-Sep-10	15-Sep-24	Granted
BE	EPC	01	04766789.4-2107	15-Sep-04	1670481	4-Aug-10	15-Sep-24	Granted
CA	PCT	01	2538202	15-Sep-04	2538202	15-Jan-13	15-Sep-24	Granted
CH	EPC	01	04766789.4-2107	15-Sep-04	1670481	4-Aug-10	15-Sep-24	Granted
DE	EPC	01	04766789.4-2107	15-Sep-04	602004028497-08	4-Aug-10	15-Sep-24	Granted
EP	PCT	01	04766789.4-2107	15-Sep-04	1670481	4-Aug-10	15-Sep-24	EP NoOpposition
ES	EPC	01	04766789.4-2107	15-Sep-04	1670481	4-Aug-10	15-Sep-24	Granted
FR	EPC	01	04766789.4-2107	15-Sep-04	1670481	4-Aug-10	15-Sep-24	Granted
GB	EPC	01	04766789.4-2107	15-Sep-04	1670481	4-Aug-10	15-Sep-24	Granted
IT	EPC	01	04766789.4-2107	15-Sep-04	1670481	4-Aug-10	15-Sep-24	Granted
JP	PCT	01	2006-525841	15-Sep-04	5371189	27-Sep-13	15-Sep-24	Granted
NL	EPC	01	04766789.4-2107	15-Sep-04	1670481	4-Aug-10	15-Sep-24	Granted
WO	ORD	01	PCT/EP2004/052170	15-Sep-04		15-Sep-24	National Phase	APAG

Invention:	1199							
Title:	Ciclesonide Formated MDI Combination Product							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
US	PCT	01	10/559383	9-Jun-04	8435497	7-May-13	25-Dec-28	Granted
WO	ORD	01	PCT/EP2004/051067	9-Jun-04			9-Jun-24	National Phase
								APAG

Invention:	1231						
Title:		Method of Treatment of Mild Asthma in Children					
Status as of:	4-Dec-15						
Owner:		APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH					
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
AL	EPE	01	AL-P-2014-55	15-Sep-04	4659	25-Dec-13	15-Sep-24
AT	EPC	01	04766791.0-1464	15-Sep-04	E646179	25-Dec-13	15-Sep-24
AU	PCT	01	2004271744	15-Sep-04	2004271744	11-Nov-10	15-Sep-24
BE	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
BG	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
CA	PCT	01	2538419	15-Sep-04	2538419	3-Jul-12	15-Sep-24
CH	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
CY	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
CZ	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
DE	EPC	01	04766791.0-1464	15-Sep-04	602004044094.9	25-Dec-13	15-Sep-24
DK	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
EE	EPC	01	04766791.0-1464	15-Sep-04	E009050	25-Dec-13	15-Sep-24
EP	PCT	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
ES	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
FI	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
FR	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
GB	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24
GR	EPC	01	2014040354	15-Sep-04	3082656	25-Dec-13	15-Sep-24
HR	EPE	01	P20140257	15-Sep-04	P20140257	25-Dec-13	15-Sep-24
HU	EPC	01	E04766791	15-Sep-04	E020444	25-Dec-13	15-Sep-24

11

Invention:	1231								
Title:	Method of Treatment of Mild Asthma in Children								
Status as of:	4-Dec-15								
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH								
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status	Owner/Co-Owner
IE	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
IT	EPC	01	04766791.0-1464	15-Sep-04	200886BE/2014	25-Dec-13	15-Sep-24	Granted	TAKDE
JP	PCT	01	2006-525842	15-Sep-04	5618452	26-Sep-14	15-Sep-24	Granted	TAKDE
JP	DIV	01	2012-137341	15-Sep-04			15-Sep-24	Examination	TAKDE
LT	EPE	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
LU	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
LV	EPE	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
MC	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
MK	EPE	01	P-2014/91	15-Sep-04	905168	25-Dec-13	15-Sep-24	Granted	TAKDE
MK	SPC	01	SPC-P-2014/91	11-Apr-14		16-Sep-24		Pending	TAKDE
NL	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
PL	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
PT	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
RO	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
SE	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
SI	EPC	01	04766791.0-1464	15-Sep-04	1670482	25-Dec-13	15-Sep-24	Granted	TAKDE
SK	EPC	01	04766791.0-1464	15-Sep-04	E16005	25-Dec-13	15-Sep-24	Granted	TAKDE
TR	EPC	01	04766791.0-1464	15-Sep-04	TR2014/02818	25-Dec-13	15-Sep-24	Granted	TAKDE
US	CON	01	13744962	15-Sep-04			15-Sep-24	Appealed	NYCO
US	PCT	01	10571311	15-Sep-04	8371292	12-Feb-13	1-Feb-28	Granted	TAKDE

Invention:	1231		
Title:	Method of Treatment of Mild Asthma in Children		
Status as of:	4-Dec-15		
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH		
Country	Case Type	Sub Case	Application Number
WO	ORD	01	PCT/EP2004/05217 2
Filing Date	Patent Number	Issue Date	Expiry Date
15-Sep-04			15-Sep-24
Owner/Co-Owner	National Phase	APAG	

Invention:	1232									
Title:	Ciclesonide in the Treatment of Asthmatic Smokers									
Status as of:	4-Dec-15									
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH									
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-Owner	
AU	PCT	01	2005235384	19-Apr-05	2005235384	23-Dec-10	19-Apr-25	Granted	TAKDE	
CA	PCT	01	2563556	19-Apr-05	2563556	29-Jan-13	19-Apr-25	Granted	TAKDE	
US	PCT	01	11/578294	19-Apr-05			19-Apr-25	Pending	TAKDE	
WO	ORD	01	PCT/EP2005/05117	19-Apr-05			19-Apr-25	National Phase	APAG	
			18							

II

Invention:	1245							
Title:	Ciclesonide Aqueous Suspensions for nebulisation							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AR	ORD	01	P0401046861	15-Dec-04			15-Dec-24	Published
AT	EPC	01	04804847.4-2117	15-Dec-04	E565139	04-Jul-12	15-Dec-24	Granted
AU	PCT	01	2004298447	15-Dec-04	2004298447	04-Aug-11	15-Dec-24	Granted
BE	EPC	01	04804847.4-2117	15-Dec-04	1697398	04-Jul-12	15-Dec-24	Granted
BR	PCT	01	PI0416854-2	15-Dec-04			15-Dec-24	Examination
BY	EAC	01	200601091	15-Dec-04	012388	30-Oct-09	15-Dec-24	Granted
CA	PCT	01	2549038	15-Dec-04	2549038	05-Aug-14	15-Dec-24	Granted
CH	EPC	01	04804847.4-2117	15-Dec-04	1697398	04-Jul-12	15-Dec-24	Granted
CL	ORD	01	31682004	14-Dec-04				Published
CN	PCT	01	200480036828.7	15-Dec-04	200480036828.7	15-Jul-09	15-Dec-24	Granted
CO	PCT	01	06-054801	15-Dec-04	1510	30-May-11	15-Dec-24	Granted
DE	EPC	01	04804847.4-2117	15-Dec-04	602004038462.3	04-Jul-12	15-Dec-24	Granted
EA	PCT	01	200601091	15-Dec-04	012388	30-Oct-09	15-Dec-24	National Phase
EG	PCT	01	549/2006	15-Dec-04			15-Dec-24	Published
EP	PCT	01	04804847.4-2117	15-Dec-04	1697398	04-Jul-12	15-Dec-24	EP
EP	DIV	11	10173237.8-1460	15-Dec-04			15-Dec-24	NoOpposition
FR	EPC	01	04804847.4-2117	15-Dec-04	1697398	04-Jul-12	15-Dec-24	Published
GB	EPC	01	04804847.4-2117	15-Dec-04	1697398	04-Jul-12	15-Dec-24	Granted
GC	ORD	01	GCCP/2004/4097	15-Dec-04				TAKDE
HK	REG	01	07104659.7	15-Dec-04	1098486B	16-Apr-10	15-Dec-24	Examination
								NYCO
								TAKDE

Invention:	1245						
Title:	Ciclesonide Aqueous Suspensions for nebulisation						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date
ID	PCT	01	W00-2006 01483	15-Dec-04	IDP034156	22-Jul-13	15-Dec-24
IL	PCT	01	175461	15-Dec-04	175461	01-Apr-14	15-Dec-24
IN	PCT	01	799MUMNP/2006	15-Dec-04	241712	21-Jul-10	15-Dec-24
IT	EPC	01	04804847 4-2117	15-Dec-04	1697398	04-Jul-12	15-Dec-24
JP	PCT	01	2006-544438	15-Dec-04	5001657	25-May-12	15-Dec-24
KR	PCT	01	10-2006-7013760	15-Dec-04	10-1086095	16-Nov-11	15-Dec-24
MX	PCT	01	PA/A/2006/006537	15-Dec-04	300528	21-Jun-12	15-Dec-24
MY	ORD	01	P120045134	14-Dec-04		14-Dec-24	Examination
NL	EPC	01	04804847 4-2117	15-Dec-04	1697398	04-Jul-12	15-Dec-24
NO	PCT	01	20063047	15-Dec-04		15-Dec-24	Published
NZ	PCT	01	547217	15-Dec-04	547217	10-Sep-09	15-Dec-24
PE	ORD	01	1247 2004	10-Dec-04	5583	09-Mar-09	10-Dec-24
PH	PCT	01	1-2006-501007	15-Dec-04	1-2006-501007	27-Feb-12	15-Dec-24
PK	ORD	01	1014/2004	14-Dec-04	139109	30-Sep-06	14-Dec-24
RU	EAC	01	200601091	15-Dec-04	012388	30-Oct-09	15-Dec-24
SG	PCT	01	200603079-5	15-Dec-04	122295	27-Feb-09	15-Dec-24
TH	ORD	01	0401004916	09-Dec-04		09-Dec-24	Pending
TW	ORD	01	093136206	16-Dec-04	1350757	21-Oct-11	16-Dec-24
UA	PCT	01	200607589	16-Dec-04	87123	25-Jun-09	15-Dec-24
US	DIV	01	14/865637	15-Dec-04		15-Dec-24	Pending

Invention:	1245							
Title:	Ciclesonide Aqueous Suspensions for nebulisation							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
VE	ORD	01	2114-04	13-Dec-04			13-Dec-24	Published
VN	PCT	01	1-2006-01159	15-Dec-04	12709	12-May-14	15-Dec-24	Granted
WO	ORD	01	PCT/EP2004/053495	15-Dec-04			15-Dec-24	National Phase
ZA	PCT	01	2006/03768	15-Dec-04	2006/3768	31-Oct-07	15-Dec-24	Granted
								TAKDE

Invention:	1465							
Title:	Stable Pharmaceutical Product comprising Ciclosporide and R,R-Formoterol							
Status as of:	4-Dec-15							
Owner:	SANOKEGB = sanofi-aventis, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
CA	PCT	01	2531646	8-Jul-04	2531646	7-Jun-11	8-Jul-24	Granted
CH	EPC	01	04743295.0-2112	8-Jul-04	1643980	3-Jul-13	8-Jul-24	Granted
DE	EPC	01	04743295.0-2112	8-Jul-04	1643980	3-Jul-13	8-Jul-24	Granted
EP	PCT	01	04743295.0-2112	8-Jul-04	1643980	3-Jul-13	8-Jul-24	EP
ES	EPC	01	04743295.0-2112	8-Jul-04	2428138	3-Jul-13	8-Jul-24	NoOpposition
FR	EPC	01	04743295.0-2112	8-Jul-04	1643980	3-Jul-13	8-Jul-24	Granted
GB	EPC	01	04743295.0-2112	8-Jul-04	1643980	3-Jul-13	8-Jul-24	Granted
IT	EPC	01	04743295.0-2112	8-Jul-04	1643980	3-Jul-13	8-Jul-24	Granted
JP	PCT	01	2006-518358	8-Jul-04	5602983	29-Aug-14	8-Jul-24	Granted
US	PCT	01	11/325875	8-Jul-04	7947744	24-May-11	8-Jul-24	Granted
US	CON	01	12/951608	8-Jul-04	8288445	16-Oct-12	8-Jul-24	Granted
WO	ORD	01	PCT/GB2004/0029	8-Jul-04			8-Jul-24	National Phase
			53					SANOKEGB

11

Invention:	1538							
Title:	Ciclesonide Containing Sterile Aqueous Suspension							
Status as of:	25-Feb-2015							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Case Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AU	PCT	01	2007339169	26-Dec-07	2007339169	9-Jan-14	26-Dec-27	Granted
CA	PCT	01	2673627	26-Dec-07			26-Dec-27	Abandoned
CH	EPC	01	078605912-1460	26-Dec-07	2124881	16-Jul-14	26-Dec-27	Granted
DE	EPC	01	078605912-1460	26-Dec-07	6020070376963	16-Jul-14	26-Dec-27	Granted
EP	PCT	01	078605912-1460	26-Dec-07	2124881	16-Jul-14	26-Dec-27	EP
FR	EPC	01	078605912-1460	26-Dec-07	2124881	16-Jul-14	26-Dec-27	NoOpposition
GB	EPC	01	078605912-1460	26-Dec-07	2124881	16-Jul-14	26-Dec-27	Granted
JP	PCT	01	2009-525822	26-Dec-07	5550339	30-May-14	26-Dec-27	Granted
US	PCT	01	12/448351	28-Dec-07	8481516	9-Jul-13	12-Nov-28	Granted
WO	ORD	01	PCT/JP2007/07539	26-Dec-07	6		26-Dec-27	National Phase

Invention:	1587						
Title:	Combination product comprising Ciclosporide and racemic formoterol						
Status as of:	4-Dec-15						
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH, SANOKEGB = Sanofi						
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date
CA	PCT	01	2527088	27-May-04	2527088	1-Mar-11	27-May-24
CH	EPC	01	04735045.9-1219	27-May-04	1626913	10-Feb-10	27-May-24
DE	EPC	01	04735045.9-1219	27-May-04	602004025463.0-08	10-Feb-10	27-May-24
EP	PCT	01	04735045.9-1219	27-May-04	1626913	10-Feb-10	27-May-24
ES	EPC	01	04735045.9-1219	27-May-04	1626913	10-Feb-10	27-May-24
FR	EPC	01	04735045.9-1219	27-May-04	1626913	10-Feb-10	27-May-24
GB	EPC	01	04735045.9-1219	27-May-04	1626913	10-Feb-10	27-May-24
IT	EPC	01	04735045.9-1219	27-May-04	1626913	10-Feb-10	27-May-24
JP	PCT	01	2006-530539	27-May-04	5175048	11-Jan-13	27-May-24
NL	EPC	01	04735045.9-1219	27-May-04	1626913	10-Feb-10	27-May-24
PL	EPC	01	04735045.9-1219	27-May-04	1626913	10-Feb-10	27-May-24
SE	EPC	01	04735045.9-1219	27-May-04	1626913	10-Feb-10	27-May-24
US	CON	03	13437569	27-May-04	8440210	14-May-13	27-May-24
US	PCT	01	111259495	27-May-04	7736673	15-Jun-10	11-Aug-24
US	CON	01	121771557	27-May-04	8029811	4-Oct-11	8-Aug-24
US	CON	02	131219046	27-May-04	8163299	24-Apr-12	27-May-24
WO	ORD	01	PC1/GB2004/002249	27-May-04			27-May-24
							National Phase

Invention:	1700						
Title:	Low Dose Ciclesonide HFA dosage form for nasal administration in children						
Status as of:	4-Dec-15						
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						

Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-Owner
AU	PCT	01	20122868880	13-Aug-12			13-Aug-32	Published	TAKDE
CA	PCT	01	2844944	13-Aug-12			13-Aug-32	Published	TAKDE
EP	PCT	01	12748426.9-1460	13-Aug-12			13-Aug-32	Published	TAKDE
MX	PCT	01	MX/A/2014/001940	13-Aug-12			13-Aug-32	Published	TAKDE
US	PCT	01	14/238055	13-Aug-12			13-Aug-32	Published	TAKDE
WO	ORD	01	PCT/EP2012/0658	13-Aug-12			13-Aug-32	National Phase	TAKDE
			12						

Invention:	B506							
Title:	Ciclesonide Intermediate and Metabolite Des-Ciclesonide							
Status as of:	4-Dec-15							
Owner:	BYK = Byk Gulden Lombeng GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AU	PTE	01	65381/94	3-Jun-04	683463	1-Apr-14	24-Feb-19	Granted
JP	PTE	01	P2007-700077	17-Jul-07	3333210	1-Apr-14	22-Dec-18	Granted
WO	ORD	00	PCT/EP94/01015	31-Mar-94				National Phase
								BYK

Invention:	B526							
Title:	Ciclesonide Silyl Intermediate Epimer Enrichment							
Status as of:	4-Dec-15							
Owner:	BYK = Byk Gulden Lombberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
JP	PTE	01	P2007-700081	18-Jul-07	3734090	8-Mar-15	27-Aug-16	Granted
WO	ORD	00	PCT/EP95/00836	7-Mar-95				National Phase
								BYK

Invention:	B551							
Title:	Ciclesonide Purification Process Epimer Enrichment							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomborg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AL	EPE	OE	AL/P03/00593	29-Aug-97	00593	11-Dec-02	29-Aug-17	Granted
AT	EPC	OE	97942897.6	29-Aug-97	E229539	11-Dec-02	29-Aug-17	Granted
AU	PCT	00	44567/97	29-Aug-97	736840	15-Nov-01	29-Aug-17	Granted
BE	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
CA	PCT	00	2264863	29-Aug-97	2264863	31-Jul-07	29-Aug-17	Granted
CH	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
CL	REG	01	1297/2004	29-Aug-97	47853	29-Aug-11	27-Jan-18	Granted
CY	REG	01	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
CY	SPC	01	CY2005010	24-Jul-09	CY2005010	30-Aug-17	29-Aug-22	Granted
CZ	PCT	00	PV1999-727	29-Aug-97	298789	19-Dec-07	29-Aug-17	Granted
DE	EPC	OE	97942897.6	29-Aug-97	69717836.6-08	11-Dec-02	29-Aug-17	Granted
DK	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
EE	SPC	01	C20050003	18-Jul-05	000008	30-Aug-17	16-Apr-19	Granted
EE	PCT	00	P199900079	29-Aug-97	03927	16-Dec-02	29-Aug-17	Granted
EP	PCT	00	97942897.6-2117	29-Aug-97	0929566	11-Dec-02	29-Aug-17	EP
ES	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
FI	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
FI	SPC	01	L20050025	7-Nov-05	267	30-Aug-17	16-Apr-19	Granted
FR	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
GB	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted

Invention:	B551							
Title:	Ciclesonide Purification Process Epimer Enrichment							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
GR	EPC	OE	97942897.6	29-Aug-97	3042697	11-Dec-02	29-Aug-17	Granted
HU	PCT	00	P9904127	29-Aug-97	228766	16-Apr-13	29-Aug-17	Granted
IE	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
IL	PCT	00	128535	29-Aug-97	128535	7-Oct-03	29-Aug-17	Granted
IT	EPC	OE	21495/BE/2003	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
JP	PTE	01	P2007-700080	18-Ju-07	3807509	30-Aug-17	21-Jul-18	Granted
JP	PCT	00	1998-5/2213	29-Aug-97	3807509	26-May-06	29-Aug-17	Granted
LT	EPE	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
LU	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
LV	EPE	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
MC	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
NL	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
PL	PCT	00	P331699	29-Aug-97	186063	30-Sep-03	29-Aug-17	Granted
PT	EPC	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
RO	EPE	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
SE	EPC	OE	97942897.6	29-Aug-97	97942897.6	11-Dec-02	29-Aug-17	Granted
SG	PCT	00	9900542-3	29-Aug-97	63880	20-Mar-01	29-Aug-17	Granted
SI	EPE	OE	97942897.6	29-Aug-97	0929566	11-Dec-02	29-Aug-17	Granted
US	PCT	00	09/147675	29-Aug-97	6187533	7-Sep-04	24-Jan-19	Granted
WO	ORD	00	PCT/EP97/04716	29-Aug-97			National Phase	TAKDE BYK

/I

Invention:	E009								
Title:	Ciclesonide Basic Substance Patent								
Status as of:	4-Dec-15								
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH								
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-Owner
AT	SPC	01	SZ 34/2008	08-Sep-08	SZ 34/2008	07-Sep-11	06-Sep-16	Granted	NYCO
AU	PTE	01	8368691	03-Jun-04	629472	07-Sep-11	06-Sep-16	Granted	TAKDE
BE	SPC	01	2005C/024	13-Jun-05	2005C/024	02-Sep-11	02-Sep-16	Granted	TAKDE
BR	PTE	01	PI1100860-1	19-Aug-09	PI1100860-1	08-Sep-10		Pending	TAKDE
CH	SPC	01	C683343/01	25-Jan-07	C683343/01	06-Sep-11	05-Sep-16	Granted	TAKDE
CL	PTE	01	1324/2004	03-Sep-15	51277	10-Jan-13		Pending	TAKDE
DE	SPC	01	122005000030-43	19-May-05	122005000030	06-Sep-11	05-Sep-16	Granted	TAKDE
ES	SPC	01	C200900045	29-Sep-09	C200900045	06-Sep-11	05-Sep-16	Granted	TAKDE
FR	SPC	01	09 C 0015	30-Mar-09	09 C 0015	29-Aug-11	27-Aug-16	Granted	TAKDE
GB	SPC	01	SPC/GB04/026	13-Aug-04	SPC/GB04/026	03-Sep-11	02-Sep-16	Granted	TAKDE
GR	SPC	01	20050800027	13-Oct-05	8000196	14-Aug-11	14-Aug-16	Granted	TAKDE
IT	SPC	01	84850	29-Sep-09	C-UB2009CCP130	29-Aug-11	28-Aug-16	Granted	TAKDE
JP	PTE	01	P2007-700076	17-Jul-07	3292928	07-Sep-11	06-Sep-16	Granted	TAKDE
LU	SPC	01	91205	09-Nov-05	91205	05-Sep-11	04-Sep-16	Granted	TAKDE
NL	SPC	01	300196	02-Jun-05	300196	31-Aug-11	29-Aug-16	Granted	TAKDE
PT	SPC	01	357	16-Mar-09	357	20-Jul-15	16-Apr-19	Granted	NYCO
RO	SPC	01	C2007033	09-May-07	C2007033	04-Sep-11	03-Sep-16	Granted	TAKDE
US	PTE	01	08278112	15-Dec-06	5462934	10-Jan-13	24-Oct-17	Granted	TAKDE

Daxas API and Respiratory IPR Patents

Invention:	1029							
Title:	Roflumilast-Tablet with PvP as Binder							
Status as of:	15-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
AE	PCT	01	267/2004	19-Feb-03			19-Feb-23	Examination
AL	EPE	01	ALP/12/04109	19-Feb-03	04085	21-Mar-12	19-Feb-23	Granted
AL	EPE	11	AL-P-2013-187	19-Feb-03	4523	15-May-13	19-Feb-23	Granted
AL	PTE	01	PTE/AL-P-2013-187	06-Feb-14	4523	20-Feb-23	19-Feb-28	Granted
AM	PTE	01	200401019	28-Mar-13	PTE008219	20-Feb-23	19-Feb-28	Granted
AM	EAC	01	200401019	19-Feb-03	008219	27-Apr-07	19-Feb-23	Granted
AR	ORD	01	P030100542	20-Feb-03			20-Feb-23	Rejected
AT	EPC	11	10173234.5-2123	19-Feb-03	E611791	15-May-13	19-Feb-23	Granted
AT	EPC	01	03704652.1-2123	19-Feb-03	E550038	21-Mar-12	19-Feb-23	Granted
AU	PCT	01	2003206924	19-Feb-03	2003206924	26-Feb-09	19-Feb-23	Granted
AZ	EAC	01	200401019	19-Feb-03	008219	27-Apr-07	19-Feb-23	Granted
AZ	PTE	01	PTE008219	09-Oct-12	PTE008219	20-Feb-23	26-Oct-23	Granted
BA	SPC	01	SDZ2013001	24-May-12	SDZ2013001	20-Feb-23	13-Jul-26	Granted
BA	PCT	01	BAP041919A	19-Feb-03	BAP041919	29-Sep-09	19-Feb-23	Granted
BE	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
BE	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
BG	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
BG	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted

Invention:	1029						
Title:	Roflumilast-Tablet with PV/P as Binder						
Status as of:	15-Feb-16						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
BR	DIV	01	BR122015029373-1	19-Feb-03			19-Feb-23 Pending
BR	PCT	01	PI0307739-0	19-Feb-03			19-Feb-23 Examination
BY	EAC	01	200401019	19-Feb-03	008219	27-Apr-07	19-Feb-23 Granted
BY	PTE	01	200401019	06-Oct-14	008219	20-Feb-23	19-Feb-28 Granted
CA	PCT	01	2475923	19-Feb-03	2475923	18-Jun-13	19-Feb-23 Granted
CH	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23 Granted
CH	EPC	11	10173234.5-2123	19-Feb-03	2268394	15-May-13	19-Feb-23 Granted
CL	ORD	01	02972003	17-Feb-03	45198	21-Jul-09	21-Jul-24 Granted
CN	DIV	01	201210231798.1	19-Feb-03			19-Feb-23 Appealed
CN	PCT	01	03804230.4	19-Feb-03	ZL03804230.4	05-Sep-12	19-Feb-23 Granted
CO	PCT	01	04092298	19-Feb-03			19-Feb-23 Appealed
CU	PCT	01	2004-0176	19-Feb-03	23370	11-Mar-08	19-Feb-23 Granted
CY	EPC	11	CY20131100654	19-Feb-03	CY1114210	15-May-13	19-Feb-23 Granted
CY	EPC	01	CY20121100493	19-Feb-03	CY1112811	21-Mar-12	19-Feb-23 Granted
CZ	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23 Granted
CZ	EPC	11	10173234.5-2123	19-Feb-03	2268394	15-May-13	19-Feb-23 Granted
DE	EPC	01	03704652.1-2123	19-Feb-03	60340327.1	21-Mar-12	19-Feb-23 Granted
DE	EPC	11	10173234.5-2123	19-Feb-03	60344089.4	15-May-13	19-Feb-23 Granted
DE	ORD	01	10207160.8-41	20-Feb-02			20-Feb-22 Examination
DK	EPC	11	10173234.5-2123	19-Feb-03	2268394	15-May-13	19-Feb-23 Granted

Invention:	1029							
Title:	Roflumilast-Tablet with PVP as Binder							
Status as of:	15-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
DK	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
DZ	PCT	01	040250	19-Feb-03	3836	05-Sep-06	19-Feb-23	Granted
EA	PCT	01	200401019	19-Feb-03	008219	27-Apr-07	19-Feb-23	National Phase
EC	PCT	01	04-5238	19-Feb-03			19-Feb-23	Published
EE	EPC	11	10173234.5-2123	19-Feb-03	E008185	15-May-13	19-Feb-23	Granted
EE	EPC	01	03704652.1-2123	19-Feb-03	E006690	21-Mar-12	19-Feb-23	Granted
EP	PCT	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Appealed
EP	DIV	11	10173234.5-1484	19-Feb-03	2258394	15-May-13	19-Feb-23	Oppo
ES	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
ES	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
FI	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
FI	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
FR	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
FR	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
GB	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
GB	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
GE	PTE	01	2003008411	10-Oct-11	P4079	20-Feb-23	19-Feb-28	Granted
GE	PCT	01	2003008411	19-Feb-03	P4079	26-Mar-07	19-Feb-23	Granted
GR	EPC	01	20120401078	19-Feb-03	3077958	21-Mar-12	19-Feb-23	Granted
GR	EPC	11	20130401449	19-Feb-03	3081192	15-May-13	19-Feb-23	Granted

Invention:	1029							
Title:	Roflumilast-Tablet with PV/P as Binder							
Status as of:	15-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
HK	REG	02	13105344.7	19-Feb-03			19-Feb-23	Pending
HK	REG	01	05109914.9	19-Feb-03	1077752B	14-Jun-13	19-Feb-23	Granted
HU	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
HU	EPC	11	E10173234	19-Feb-03	E018899	15-May-13	19-Feb-23	Granted
ID	PCT	01	W00-2004.01767	19-Feb-03	IDP0023575	10-Jun-09	19-Feb-23	Granted
IE	EPC	11	10113234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
IE	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
IL	PCT	01	162843	19-Feb-03	162843	01-Jul-15	19-Feb-23	Granted
IL	DIV	01	237796	19-Feb-03			19-Feb-23	Pending
IN	PCT	01	2004/00369/MUMN P	19-Feb-03	220907	10-Jun-08	19-Feb-23	Granted
IS	PCT	01	7410	19-Feb-03			19-Feb-23	Published
IT	EPC	11	26624BE/2013	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
IT	EPC	01	251677BE/2012	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
JP	PCT	01	2003-569234	19-Feb-03	4163120	01-Aug-08	19-Feb-23	Granted
KG	EAC	01	200401019	19-Feb-03	008219	27-Apr-07	19-Feb-23	Granted
KR	DIV	01	10-2010-7019428	19-Feb-03	10-1386843	11-Apr-14	19-Feb-23	Granted
KR	PCT	01	10-2004-7012904	19-Feb-03	10-1253033	04-Apr-13	19-Feb-23	Granted
KS	REG	01	594	19-Feb-03	237	12-Jan-12	19-Feb-23	Granted
KZ	EAC	01	200401019	19-Feb-03	068219	27-Apr-07	19-Feb-23	Granted
LT	EPE	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted

Invention:	1029							
Title:	Roflumilast-Tablet with PVP as Binder							
Status as of:	15-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH; TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
LT	EPE	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
LU	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
LU	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
LV	EPE	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
LV	EPE	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
MA	PCT	01	27774	19-Feb-03	27100	20-Dec-04	19-Feb-23	Granted
MC	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
MC	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
MD	PTE	01	PTE008219	23-Apr-12	PTE008219	20-Feb-23	28-Dec-26	Granted
MD	EAC	01	200401019	19-Feb-03	008219	27-Apr-07	19-Feb-23	Granted
ME	REG	01	P-855/08	19-Feb-03	00566	20-Dec-11	19-Feb-23	Granted
MK	EPE	01	P/EP-2012/194	19-Feb-03	904313	21-Mar-12	19-Feb-23	Granted
MK	EPE	11	P/EP-2013/299	19-Feb-03	904840	15-May-13	19-Feb-23	Granted
MX	PCT	01	PA/A/2004/005759	19-Feb-03	294128	03-Jan-12	19-Feb-23	Granted
MX	DIV	01	MX/A/2011/009569	19-Feb-03	310790	24-Jun-13	19-Feb-23	Granted
MY	ORD	01	P120030495	13-Feb-03	MY-140561-A	31-Dec-09	13-Feb-23	Granted
NL	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23	Granted
NL	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23	Granted
NO	PCT	01	20043904	19-Feb-03	332844	22-Jan-13	19-Feb-23	Granted
NZ	PCT	01	535197	19-Feb-03	535197	15-Mar-07	19-Feb-23	Granted

Invention:	1029						
Title:	Roflumilast-Tablet with PVF as Binder						
Status as of:	15-Feb-16						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
PE	ORD	01	169/2003	18-Feb-03			18-Feb-23
PH	PCT	01	1-2004-501237	19-Feb-03	1-2004-501237	20-Dec-11	19-Feb-23
PK	ORD	01	127/2003	18-Feb-03	138447	18-Jun-05	20-Feb-22
PL	PCT	01	P370595	19-Feb-03			19-Feb-23
PT	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23
PT	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23
RO	EPE	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23
RO	EPE	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23
RS	PCT	01	P-0736/04	19-Feb-03	52548	09-Jan-13	19-Feb-23
RS	SPC	01	SDZ-2013/00008	29-Oct-13	5	20-Feb-23	23-Aug-26
RU	PTE	01	008219	23-Jan-12	008219	20-Feb-23	22-Aug-26
RU	EAC	01	200401019	19-Feb-03	008219	27-Apr-07	19-Feb-23
SE	EPC	01	03704652.1-2123	19-Feb-03	1478399	21-Mar-12	19-Feb-23
SE	EPC	11	10173234.5-2123	19-Feb-03	2258394	15-May-13	19-Feb-23
SG	PCT	01	200404888-0	19-Feb-03	107189	29-Sep-06	19-Feb-23
SI	EPC	11	P200332288	19-Feb-03	2258394	15-May-13	19-Feb-23
SI	EPC	01	P200332160	19-Feb-03	1478399	21-Mar-12	19-Feb-23
SK	EPC	01	03704652.1-2123	19-Feb-03	E11815	21-Mar-12	19-Feb-23
SK	EPC	11	10173234.5-2123	19-Feb-03	E14503	15-May-13	19-Feb-23
TH	ORD	01	0301000447	11-Feb-03		11-Feb-23	Examination APAG

Invention:	1029						
Title:	Roflumilast-Tablet with PVP as Binder						
Status as of:	15-Feb-16						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
TJ	EAC	01	200401019	19-Feb-03	008219	27-Apr-07	19-Feb-23
TM	EAC	01	200401019	19-Feb-03	008219	27-Apr-07	19-Feb-23
TN	PCT	01	SN04.124	19-Feb-03	18774	14-May-07	19-Feb-23
TR	EPC	11	10173234.5-2123	19-Feb-03	TR2013/09408	15-May-13	19-Feb-23
TR	EPC	01	03704652.1-2123	19-Feb-03	TR2012/06684	21-Mar-12	19-Feb-23
TW	PTE	01		05-Oct-12		19-Feb-23	Pending
TW	ORD	01	092103296	18-Feb-03	1363636	11-May-12	18-Feb-23
UA	PCT	01	20040907576	19-Feb-03	84266	10-Oct-08	19-Feb-23
UA	PTE	01	20040907576	16-Feb-11	84266	20-Feb-23	19-Feb-28
US	CON	04	13/874065	19-Feb-03		19-Feb-23	Pending
US	CON	09	14/731964	19-Feb-03		19-Feb-23	Pending
US	CON	08	14/735004	19-Feb-03		19-Feb-23	Pending
US	CON	07	14/735015	19-Feb-03		19-Feb-23	Pending
US	CON	05	14/038666	19-Feb-03		19-Feb-23	Published
US	PCT	01	10/505138	19-Feb-03	7951397	31-May-11	27-Jan-24
US	CON	02	13/008842	19-Feb-03	8431154	30-Apr-13	19-Feb-23
VE	ORD	01	247-03	20-Feb-03		20-Feb-23	Rejected
VN	PCT	01	1-2004-00934	19-Feb-03	12935	15-Jul-14	19-Feb-23
WO	ORD	01	PCT/EP03/01650	19-Feb-03		19-Feb-23	National Phase
ZA	PCT	01	2004/6644	19-Feb-03	2004/06644	31-May-06	19-Feb-23
							Granted
							TAKDE

Invention:	1029							
Title:	Refillable tablet with PVP as binder							
Status as of:	15-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case	Sub	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Owner/Co-Owner
ZW	Type	Case						
ZW	PCT	01	42/2004	19-Feb-03	42/2004	11-Feb-05	19-Feb-23	Granted
								TAKDE

11

Invention:	1084							
Title:	Combination PDE4 or PDE3/4 Inhibitor and Histamine Antagonist							
Status as of:	15-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
CH	EPC	01	03708130.4-2123	25-Feb-03	1482938	8-Aug-07	25-Feb-23	Granted
CH	EPC	11	07112823.5-2112	25-Feb-03	1849468	5-Dec-12	25-Feb-23	Granted
DE	EPC	01	03708130.4-2123	25-Feb-03	60315426.3-08	8-Aug-07	25-Feb-23	Granted
DE	EPC	11	07112823.5-2112	25-Feb-03	60342796.0	5-Dec-12	25-Feb-23	Granted
EP	DIV	11	07112823.5-2112	25-Feb-03	1849468	5-Dec-12	25-Feb-23	EP
EP	PCT	01	03708130.4-2123	25-Feb-03	1482938	8-Aug-07	25-Feb-23	NoOpposition
FR	EPC	11	07112823.5-2112	25-Feb-03	1849468	5-Dec-12	25-Feb-23	Granted
FR	EPC	01	03708130.4-2123	25-Feb-03	1482938	8-Aug-07	25-Feb-23	Granted
GB	EPC	11	07112823.5-2112	25-Feb-03	1849468	5-Dec-12	25-Feb-23	Granted
GB	EPC	01	03708130.4-2123	25-Feb-03	1482938	8-Aug-07	25-Feb-23	Granted
JP	PCT	01	2003-572572	25-Feb-03	5150034	7-Dec-12	25-Feb-23	Granted
WO	ORD	01	PCT/EP03/01876	25-Feb-03			25-Feb-23	National Phase
								APAG

Inventor:	1095					
Title:	Combination PDE4 or PDE3/4 Inhibitor and Leukotriene Antagonist					
Status as of:	15-Feb-16					
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH					
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date
CH	EPC	01	02798730.4-2107	17-Sep-02	1429843	27-Dec-06
DE	EPC	01	02798730.4-2107	17-Sep-02	60217139.3-08	27-Dec-06
EP	PCT	01	02798730.4-2107	17-Sep-02	1429843	27-Dec-06
FR	EPC	01	02798730.4-2107	17-Sep-02	1429843	27-Dec-06
GB	EPC	01	02798730.4-2107	17-Sep-02	1429843	27-Dec-06
WO	ORD	01	PCT/EP2002/0104	17-Sep-02		17-Sep-22
		23				National Phase
						APAG

Invention:	1117							
Title:	Improved Process for the Preparation of Roflumilast							
Status as of:	15-Feb-16							
Owner:	APAG = ALTANA Pharma AG; NYCO = Nycomed GmbH; TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
AL	EPE	01	AL/P/09/03253	8-Mar-04	03238	4-Nov-09	8-Mar-24	Granted
AM	PTE	01	200501350	28-Mar-13	009985	9-Mar-24	8-Mar-29	Granted
AM	EAC	01	200501350	8-Mar-04	009985	28-Apr-08	8-Mar-24	Granted
AR	ORD	01	P040100762	10-Mar-04			10-Mar-24	Appealed
AT	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
AU	PCT	01	2004220357	8-Mar-04	2004220357	13-Jan-11	8-Mar-24	Granted
AZ	EAC	01	200501350	8-Mar-04	009985	28-Apr-08	8-Mar-24	Granted
BA	PCT	01	BAP052186A	8-Mar-04	BAP052186	9-Dec-09	8-Mar-24	Granted
BE	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
BG	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
BG	SPC	01	10/007	10-Sep-10	2010/007	9-Mar-24	5-Jul-25	Granted
BR	PCT	01	P10406427-5	8-Mar-04			8-Mar-24	Examination
BY	EAC	01	200501350	8-Mar-04	009985	28-Apr-08	8-Mar-24	Granted
CA	PCT	01	2503290	8-Mar-04	2503290	4-Dec-12	8-Mar-24	Granted
CH	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
CN	PCT	01	200480001216.4	8-Mar-04	ZL200480001216.	25-Mar-09	8-Mar-24	Granted
CY	EPC	01	CY20091101294	8-Mar-04	4		8-Mar-24	TAKDE
CZ	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
DE	EPC	01	04718315.7-2101	8-Mar-04	602004023921.6	4-Nov-09	8-Mar-24	Granted
DK	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted

Invention:	1117							
Title:	Improved Process for the Preparation of Rofumilast							
Status as of:	15-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
EA	PCT	01	200301350	8-Mar-04	009985	28-Apr-08	8-Mar-24	National Phase
EE	SPC	01	C20100008	16-Nov-10	00033	9-Mar-24	5-Jul-25	Granted
EE	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
EP	PCT	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	EP
ES	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	NoOpposition
FI	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
FR	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
GB	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
GR	EPC	01	04718315.7-2101	8-Mar-04	3070772	4-Nov-09	8-Mar-24	Granted
HK	REG	01	06105594.3	8-Mar-04	1085480B	11-Dec-09	8-Mar-24	Granted
HR	PCT	01	P200503399A	8-Mar-04	P200503399	12-Sep-13	8-Mar-24	Granted
HR	SPC	01	S20130022A	10-Dec-13		9-Mar-24	Pending	TAKDE
HU	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
IE	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
IL	PCT	01	168170	8-Mar-04	168170	31-Mar-11	8-Mar-24	Granted
IN	PCT	01	200500303/MUMN P	8-Mar-04	209058	20-Aug-07	8-Mar-24	Granted
IS	PCT	01	7810	8-Mar-04	2723	15-Mar-11	8-Mar-24	Granted
IS	SPC	01	SPC49	13-Apr-11	SPC49	9-Mar-24	4-Jul-25	Granted
IT	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted

Invention:	1117						
Title:	Improved Process for the Preparation of Roflumilast						
Status as of:	15-Feb-16						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
JP	PCT	01	2006-505451	8-Mar-04	4742026	13-May-11	8-Mar-24
KG	EAC	01	200501350	8-Mar-04	009985	28-Apr-08	8-Mar-24
KR	PCT	01	10-2005-7007425	8-Mar-04	10-1179012	27-Aug-12	8-Mar-24
KS	REG	01	595	8-Mar-04	281	17-Jan-12	8-Mar-24
KZ	EAC	01	200501350	8-Mar-04	009985	28-Apr-08	8-Mar-24
LT	SPC	01	PA2010-010	19-Jul-10	C1606261	9-Mar-24	5-Jul-25
LT	EPE	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24
LJ	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24
LV	EPE	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24
MC	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24
MD	EAC	01	200501350	8-Mar-04	009985	28-Apr-08	8-Mar-24
ME	REG	01	P-867/08	8-Mar-04	00524	10-Oct-11	8-Mar-24
MK	EPE	01	04718315.7-2101	8-Mar-04	903423	4-Nov-09	8-Mar-24
MX	PCT	01	PA/A/2004/008070	8-Mar-04	254050	31-Jan-08	8-Mar-24
NL	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24
NO	PCT	01	20051957	8-Mar-04	329301	27-Sep-10	8-Mar-24
NZ	PCT	01	539542	8-Mar-04	539542		8-Mar-24
PH	PCT	01	1-2005-501594	8-Mar-04	1-2005-501594	29-Nov-13	8-Mar-24
PL	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24
PT	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24

Invention:	1117							
Title:	Improved Process for the Preparation of Rofumilast							
Status as of:	16-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
RO	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
RO	SPC	01	C2010014	4-Oct-10	C2010014	9-Mar-24	5-Jul-25	Granted
RS	PCT	01	P 2005/0669	8-Mar-04	52908	30-Oct-13	8-Mar-24	Granted
RU	EAC	01	200501350	8-Mar-04	009985	28-Apr-08	8-Mar-24	Granted
SE	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
SG	PCT	01	200504975-4	8-Mar-04	114142	31-Oct-07	8-Mar-24	Granted
SI	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
SK	EPC	01	04718315.7-2101	8-Mar-04	1606261	4-Nov-09	8-Mar-24	Granted
TJ	EAC	01	200501350	8-Mar-04	009985	28-Apr-08	8-Mar-24	Granted
TM	EAC	01	200501350	8-Mar-04	009985	28-Apr-08	8-Mar-24	Granted
TR	EPC	01	04718315.7-2101	8-Mar-04	TR2010/00465	4-Nov-09	8-Mar-24	Granted
TW	ORD	01	093106329	10-Mar-04	1340741	21-Apr-11	10-Mar-24	Granted
US	CON	04	13860248	8-Mar-04	8604064	10-Dec-13	8-Mar-24	Granted
US	CON	03	13860264	8-Mar-04	8618142	31-Dec-13	8-Mar-24	Granted
US	CON	02	131547945	8-Mar-04	8536206	17-Sep-13	8-Mar-24	Granted
US	PCT	01	10/531720	8-Mar-04	7470791	30-Dec-08	18-Oct-25	Granted
WO	ORD	01	PCT/EP2004/05022	8-Mar-04	72	8-Mar-24	National Phase	APAG
ZA	PCT	01	2005/03191	8-Mar-04	2005/03191	22-Feb-06	8-Mar-24	Granted
								TAKDE

/1

Invention:	1148						
Title:	Combination of Roflumilast with R,R-Formoterol						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
AL	EPE	01	AL/P0802748	26-Nov-03	02812	2-Jul-08	26-Nov-23
AM	EAC	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23
AT	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
AU	PCT	01	200328169	26-Nov-03	2003288169	16-Aug-10	26-Nov-23
AZ	EAC	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23
BA	PCT	01	BAP052209A	26-Nov-03	BAP052209	9-Dec-09	26-Nov-23
BE	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
BG	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
BY	EAC	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23
CA	PCT	01	2506956	26-Nov-03	2506956	2-Oct-12	26-Nov-23
CH	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
CY	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
CZ	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
DE	EPC	01	03780056.2-1216	26-Nov-03	60321954.3-08	2-Jul-08	26-Nov-23
DK	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
EA	PCT	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23
EE	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
EP	PCT	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
ES	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
FI	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23

Invention:	1148							
Title:	Combination of Roflumilast with RR-Formoterol							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG; NYCO = Nycomed GmbH; TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
FR	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted
GB	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted
GR	EPC	01	03780056.2-1216	26-Nov-03	3066427	2-Jul-08	26-Nov-23	Granted
HK	REG	01	08102227.5	26-Nov-03	1081862B	29-May-09	26-Nov-23	Granted
HR	PCT	01	P20050580A	26-Nov-03	P20050580	20-Mar-14	26-Nov-23	Granted
HU	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted
ID	PCT	01	W00-2005.01281	26-Nov-03	IDP0029854	11-Jan-12	26-Nov-23	Granted
IE	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted
IL	PCT	01	168307	26-Nov-03	168307	31-Mar-11	26-Nov-23	Granted
IN	PCT	01	2005/00636/MUM/N P	26-Nov-03	211369	26-Oct-07	26-Nov-23	Granted
IS	PCT	01	7899	26-Nov-03	2576	15-Feb-10	26-Nov-23	Granted
IT	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted
KG	EAC	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23	Granted
KS	REG	01	575	26-Nov-03	262	17-Jan-12	26-Nov-23	Granted
KZ	EAC	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23	Granted
LT	EPE	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted
LU	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted
LV	EPE	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted
MA	PCT	01	28342	26-Nov-03	27538	1-Sep-05	26-Nov-23	Granted
MC	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted

Invention:	1148						
Title:	Combination of Roflumilast with R,R-Formoterol						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date
MD	EAC	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23
ME	REG	01	P-78108	26-Nov-03	00488	10-Oct-11	26-Nov-23
MK	EPE	01	03780056.2-1216	26-Nov-03	903001	2-Jul-08	26-Nov-23
MX	PCT	01	PA/A/2005/005438	26-Nov-03	281399	15-Oct-08	26-Nov-23
NL	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
NO	PCT	01	200503023	26-Nov-03	334148	16-Dec-13	26-Nov-23
NZ	PCT	01	540658	26-Nov-03	540658	12-Jul-07	26-Nov-23
PH	PCT	01	1-2005-500932	26-Nov-03	1-2005-500932	5-Jun-09	26-Nov-23
PL	PCT	01	P375632	26-Nov-03	214869	20-Feb-13	26-Nov-23
PT	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
RO	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
RS	PCT	01	P-2005/0383	26-Nov-03	51082	18-Jun-10	26-Nov-23
RU	EAC	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23
SE	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
SG	PCT	01	200503202-4	26-Nov-03	113101	31-Jan-08	26-Nov-23
SI	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
SK	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23
TJ	EAC	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23
TM	EAC	01	200500865	26-Nov-03	009990	28-Apr-08	26-Nov-23
TN	PCT	01	SN05.130	26-Nov-03	19049	17-Jul-07	26-Nov-23

Invention:	1148							
Title:	Combination of Roflumilast with R,R-Formoterol							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
TR	EPC	01	03780056.2-1216	26-Nov-03	1567140	2-Jul-08	26-Nov-23	Granted
UA	PCT	01	A200505965	26-Nov-03	83017	10-Jun-08	26-Nov-23	Granted
VN	PCT	01	1-2005-00840	26-Nov-03	7641	7-Apr-09	26-Nov-23	Granted
WO	ORD	01	PCT/EP03/13266	26-Nov-03			26-Nov-23	National Phase
ZA	PCT	01	2005/03307	26-Nov-03	2005/03307	29-Nov-06	26-Nov-23	Granted
ZW	PCT	01	15/2005	26-Nov-03	15/2005	4-Nov-05	26-Nov-23	Granted
								NYCO

Invention:	1150							
Title:	Combination of Roflumilast with Formoterol							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AL	EPE	01	AL/P/08/02749	26-Nov-03	02680	22-Jan-09	26-Nov-23	Granted
AM	EAC	01	200500774	26-Nov-03	009935	28-Apr-08	26-Nov-23	Granted
AT	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
AU	PCT	01	2003292120	26-Nov-03	2003292120	6-May-10	26-Nov-23	Granted
AZ	EAC	01	200500774	26-Nov-03	009935	28-Apr-08	26-Nov-23	Granted
BA	PCT	01	BAP052210A	26-Nov-03	BAP052210	10-Dec-09	26-Nov-23	Granted
BE	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
BG	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
BY	EAC	01	200500774	26-Nov-03	009935	28-Apr-08	26-Nov-23	Granted
CA	PCT	01	2506962	26-Nov-03	2506662	3-Jan-12	26-Nov-23	Granted
CH	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
CN	PCT	01	200380103745.0	26-Nov-03	ZL2003380103745.	7-Nov-07	26-Nov-23	Granted
			0					TAKDE
CY	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
CZ	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
DE	EPC	01	03767663.2-1216	26-Nov-03	60321963.5-08	2-Jul-08	26-Nov-23	Granted
DK	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
EA	PCT	01	200500774	26-Nov-03	009935	28-Apr-08	26-Nov-23	National Phase
EE	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
EP	PCT	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	EP
								NoOpposition

Invention:	1150							
Title:	Combination of Roflumilast with Formoterol							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
ES	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
FI	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
FR	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
GB	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
GR	EPC	01	03767663.2-1216	26-Nov-03	3066428	2-Jul-08	26-Nov-23	Granted
HK	REG	01	06102226.6	26-Nov-03	1081881B	29-May-09	26-Nov-23	Granted
HR	PCT	01	P20050579A	26-Nov-03	P20050579	31-Jan-14	26-Nov-23	Granted
HU	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
ID	PCT	01	W00-2005.01282	26-Nov-03	1D0021888	4-Sep-08	26-Nov-23	Granted
IE	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
IL	PCT	01	1683308	26-Nov-03	1683308	31-Mar-11	26-Nov-23	Granted
IN	PCT	01	2005/00635/MUMN P	26-Nov-03	219467	7-May-08	26-Nov-23	Granted
IS	PCT	01	7898	26-Nov-03	2575	15-Feb-10	26-Nov-23	Granted
IT	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
KG	EAC	01	2005/00774	26-Nov-03	009835	28-Apr-08	26-Nov-23	Granted
KR	PCT	01	10-2005-7008210	26-Nov-03	10-1071798	4-Oct-11	26-Nov-23	Granted
KS	REG	01	567	26-Nov-03	260	17-Jan-12	26-Nov-23	Granted
KZ	EAC	01	2005/00774	26-Nov-03	009835	28-Apr-08	26-Nov-23	Granted
LT	EPE	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
LU	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted

Invention:	1150							
Title:	Combination of Roflumilast with Formoterol							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
LV	EPE	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
MA	PCT	01	28343	26-Nov-03	27539	1-Sep-05	26-Nov-23	Granted
MC	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
MD	EAC	01	200500774	26-Nov-03	009935	28-Apr-08	26-Nov-23	Granted
ME	REG	01	P-782/08	26-Nov-03	00489	10-Oct-11	26-Nov-23	Granted
MK	EPE	01	03767663.2-1216	26-Nov-03	903000	2-Jul-08	26-Nov-23	Granted
MX	PCT	01	PA/A/2005/005437	26-Nov-03	261400	15-Oct-08	26-Nov-23	Granted
NL	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
NO	PCT	01	20052989	26-Nov-03	334247	20-Jan-14	26-Nov-23	Granted
NZ	PCT	01	540659	26-Nov-03	540659	13-Sep-07	26-Nov-23	Granted
PH	PCT	01	1-2005-500883	26-Nov-03	1-2005-500883	30-Sep-09	26-Nov-23	Granted
PL	PCT	01	P377732	26-Nov-03	PL216752	17-Oct-13	26-Nov-23	Granted
PT	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
RO	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
RS	PCT	01	P-2005/0382	26-Nov-03	51081	18-Jun-10	26-Nov-23	Granted
RU	EAC	01	200500774	26-Nov-03	009935	28-Apr-08	26-Nov-23	Granted
SE	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
SG	PCT	01	200503203-2	26-Nov-03	113102	30-May-07	26-Nov-23	Granted
SI	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted
SK	EPC	01	03767663.2-1216	26-Nov-03	1567139	2-Jul-08	26-Nov-23	Granted

Invention:	1150						
Title:	Combination of Roflumilast with Formoterol						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
TJ	EAC	01	200500774	26-Nov-03	009935	28-Apr-08	26-Nov-23
TM	EAC	01	200500774	26-Nov-03	009935	28-Apr-08	26-Nov-23
TN	PCT	01	SN05.131	26-Nov-03	19050	17-Jul-07	26-Nov-23
TR	EPC	01	03767663.2-1216	26-Nov-03	TR2008/07154	2-Jul-08	26-Nov-23
UA	PCT	01	A200505966	26-Nov-03	83018	10-Jun-08	26-Nov-23
VN	PCT	01	1-2005-00841	26-Nov-03	7812	6-Jul-09	26-Nov-23
WO	ORD	01	PCT/EP2003/0132	26-Nov-03		26-Nov-23	National Phase APAG
ZA	PCT	01	75				
ZW	PCT	01	2005/03308	26-Nov-03	2005/03308	29-Nov-06	26-Nov-23
			13/2005	26-Nov-03	13/2005	4-Nov-05	26-Nov-23
						Granted	
							NYCO

Invention:	11158							
Title:	Combination of PDE4 and PDE5 Inhibitors							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
CH	EPC	01	04766017.0-1456	19-May-04	1628682	25-Sep-13	19-May-24	Granted
DE	EPC	01	04766017.0-1456	19-May-04	602004043421.3	25-Sep-13	19-May-24	Granted
EP	PCT	01	04766017.0-1456	19-May-04	1628682	25-Sep-13	19-May-24	EP
FR	EPC	01	04766017.0-1456	19-May-04	1628682	25-Sep-13	19-May-24	NoOpposition
GB	EPC	01	04766017.0-1456	19-May-04	1628682	25-Sep-13	19-May-24	Granted
WO	ORD	01	PCT/EP2004/050869	19-May-04			19-May-24	National Phase
								APAG

Invention:	1171						
Title:	Combination Roflumilast/Tiotropium Bromide Inhalative						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
AT	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
BE	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
BG	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
CA	PCT	01	2519679	26-Mar-04	2519679	28-Aug-12	26-Mar-24
CH	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
CY	EPC	01	CY20081100350	26-Mar-04	CY1110373	23-Jan-08	26-Mar-24
CZ	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
DE	EPC	01	04723608.8-2123	26-Mar-04	602004011494.4-08	23-Jan-08	26-Mar-24
DK	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
EE	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
EP	PCT	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
ES	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
FI	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
FR	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
GB	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
GR	EPC	01	04723608.8-2123	26-Mar-04	3065003	23-Jan-08	26-Mar-24
HU	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
IE	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
IT	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24

Invention:	1171						
Title:	Combination Roflumilast/Tiotropium Bromide Inhalative						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
LU	EPC	01	04723608.8	26-Mar-04	1610787	23-Jan-08	26-Mar-24
MC	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
MX	PCT	01	PA/A/2005/010160	26-Mar-04	258201	9-Apr-08	26-Mar-24
NL	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
PL	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
PT	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
RO	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
SE	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
SI	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
SK	EPC	01	04723608.8-2123	26-Mar-04	1610787	23-Jan-08	26-Mar-24
TR	EPC	01	04723608.8-2123	26-Mar-04	TR2008025599	23-Jan-08	26-Mar-24
WO	ORD	01	PCT/EP2004/05037	26-Mar-04		26-Mar-24	National Phase
		6					APAG

Invention:	1391						
Title:	Roflumilast for Use in the Treatment of Chronic Pulmonary Hypertension						
Status as of:	18-Feb-16						
Owner:	NYCC = Nycomed GmbH, TAKDE = Takeda GmbH						

Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status	Owner/Co-Owner
CH	EPC	11	11168764.6-1453	12-Apr-06	2366393	7-Aug-13	12-Apr-26	Granted	TAKDE
DE	EPC	11	11168764.6-1453	12-Apr-06	602006037788.6	7-Aug-13	12-Apr-26	Granted	TAKDE
EP	DIV	11	11168764.6-1453	12-Apr-06	2366393	7-Aug-13	12-Apr-26	EP	TAKDE
FR	EPC	11	11168764.6-1453	12-Apr-06	2366393	7-Aug-13	12-Apr-26	No Opposition	TAKDE
GB	EPC	11	11168764.6-1453	12-Apr-06	2366393	7-Aug-13	12-Apr-26	Granted	TAKDE
US	PCT	01	11/918397	12-Apr-06	8648100	11-Feb-14	29-May-29	Granted	TAKDE
WO	ORD	01	PCT/EP2006/06155	12-Apr-06	7		12-Apr-26	National Phase	NYCO

Invention:	1474	Combination of Rofumilast with Statins/HMG-CoA Reductase Inhibitors					
Title:	4-Dec-15						
Status as of:							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
AL	EPE	11	AL-P-2014-0000003	3-Jul-07	4621	30-Oct-13	3-Jul-27
AL	EPE	12	AL-P-2014-176	3-Jul-07	4784	7-May-14	3-Jul-27
AT	EPC	12	11164518.0-1464	3-Jul-07	E689058	7-May-14	3-Jul-27
AT	EPC	11	11164516.4-1464	3-Jul-07	E636246	30-Oct-13	3-Jul-27
AU	PCT	01	2007271186	3-Jul-07	2007271186	8-Aug-13	3-Jul-27
AU	DIV	02	2013203094	3-Jul-07			3-Jul-27
AU	DIV	01	2013203070	3-Jul-07			3-Jul-27
BA	EPE	11	E01343	3-Jul-07	2359826	30-Oct-13	3-Jul-27
BA	EPE	12	E01490	3-Jul-07	2363130	7-May-14	3-Jul-27
BE	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27
BE	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27
BG	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27
BG	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27
BR	PCT	01	PI0713768-0	3-Jul-07			3-Jul-27
CA	PCT	01	2656366	3-Jul-07			3-Jul-27
CH	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27
CH	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27
CN	PCT	01	200780025240.5	3-Jul-07	ZL200780025240.5	5-Sep-12	3-Jul-27
CY	EPC	11	CY20141100008	3-Jul-07	5		
CY	EPC	12	CY20141100621	3-Jul-07	CY1114742	30-Oct-13	3-Jul-27
CY	EPC	12	CY1115462	3-Jul-07	CY1115462	7-May-14	3-Jul-27

Invention:	1474							
Title:	Combination of Roflumilast with Statins/HMG-CoA Reductase Inhibitors							
Status as of:	4-Dec-15							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
CZ	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
CZ	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
DE	EPC	12	11164518.0-1464	3-Jul-07	602007036649.6	7-May-14	3-Jul-27	Granted
DE	EPC	11	11164516.4-1464	3-Jul-07	602007033588.4	30-Oct-13	3-Jul-27	Granted
DE	EPC	01	07780079-2123	3-Jul-07	602007019110.6	30-Nov-11	3-Jul-27	Granted
DK	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
DK	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
EA	PCT	01	200900073	3-Jul-07	021461	30-Jun-15	3-Jul-27	National Phase
EA	DIV	11	201401042	3-Jul-07		3-Jul-27		Examination
EE	EPC	11	11164516.4-1464	3-Jul-07	E008853	30-Oct-13	3-Jul-27	Granted
EE	EPC	12	11164518.0-1464	3-Jul-07	E009424	7-May-14	3-Jul-27	Granted
EP	DIV	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	EP NoOpposition
EP	DIV	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	EP NoOpposition
EP	PCT	01	07780079-2123	3-Jul-07	2040707	30-Nov-11	3-Jul-27	EP NoOpposition
ES	EPC	11	11164516.4-1464	3-Jul-07	2443342	30-Oct-13	3-Jul-27	Granted
ES	EPC	01	07780079-2123	3-Jul-07	2378281	30-Nov-11	3-Jul-27	Granted
ES	EPC	12	11164518.0-1464	3-Jul-07	2489265	7-May-14	3-Jul-27	Granted
FI	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted

Invention:	1474							
Title:	Combination of Roflumilast with Statins/HMG-CoA Reductase Inhibitors							
Status as of:	4-Dec-15							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
FI	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
FR	EPC	01	07787007.9-2123	3-Jul-07	2040707	30-Nov-11	3-Jul-27	Granted
FR	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
FR	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
GB	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
GB	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
GB	EPC	01	07787007.9-2123	3-Jul-07	2040707	30-Nov-11	3-Jul-27	Granted
GR	EPC	11	20130402727	3-Jul-07	3082445	30-Oct-13	3-Jul-27	Granted
GR	EPC	12	20140401077	3-Jul-07	3083627	7-May-14	3-Jul-27	Granted
HR	EPE	11	11164516.4-1464	3-Jul-07	P20140073	30-Oct-13	3-Jul-27	Granted
HR	EPE	12	11164518.0-1464	3-Jul-07	P20140707	7-May-14	3-Jul-27	Granted
HU	EPC	11	E11164516	3-Jul-07	E0218923	30-Oct-13	3-Jul-27	Granted
HU	EPC	12	E11164518	3-Jul-07	E021502	7-May-14	3-Jul-27	Granted
IE	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
IE	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
IL	DIV	01	221307	3-Jul-07	221307	1-Dec-14	3-Jul-27	Granted
IL	DIV	02	221309	3-Jul-07	221309	1-Apr-15	3-Jul-27	Granted
IL	PCT	01	195433	3-Jul-07	195433	29-May-13	3-Jul-27	Granted
IN	PCT	01	214MUMNP/2009	3-Jul-07	286349	1-Jan-14	3-Jul-27	Granted
IN	DIV	01	349MUMNP/2013	3-Jul-07		3-Jul-27	Published	TAKDE

Invention:	1474							
Title:	Combination of Rosfumilast with Statins/HMG-CoA Reductase Inhibitors							
Status as of:	4-Dec-15							
Owner:	NYCO = Nycomed GmbH; TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
IN	DIV	02	351/MUMNP/2013	3-Jul-07	2363130	7-May-14	3-Jul-27	Published
IS	EPC	12	11164518.0-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
IS	EPC	11	11164518.4-1464	3-Jul-07	2040707	30-Nov-11	3-Jul-27	Granted
IT	EPC	01	07787007.9-2123	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
IT	EPC	12	25540/BE/2014	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
IT	EPC	11	11164518.4-1464	3-Jul-07	5349302	30-Aug-13	3-Jul-27	Granted
JP	PCT	01	2009-517256	3-Jul-07	10-1433394	18-Aug-14	3-Jul-27	Granted
KR	PCT	01	10-2009-7001868	3-Jul-07	2363130	30-Oct-13	3-Jul-27	Pending
KS	REG	02	KS/P/2014/6	3-Jul-07	663	5-Feb-13	3-Jul-27	Granted
KS	REG	01	237	3-Jul-07	2363130	25-Aug-14	3-Jul-27	Granted
LT	EPC	12	11164518.0-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
LT	EPC	11	11164518.4-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
LU	EPC	12	11164518.0-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
LU	EPC	11	11164518.4-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
LV	EPC	12	11164518.0-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
LV	EPC	11	11164518.4-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
MC	EPC	11	11164518.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
MC	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
ME	REG	03	P-2014-91	3-Jul-07	01901	7-May-14	3-Jul-27	Granted
ME	REG	02	P-2014-9	3-Jul-07	01648	30-Oct-13	3-Jul-27	Granted

Invention:	1474							
Title:	Combination of Roflumilast with Statins/HMG-CoA Reductase Inhibitors							
Status as of:	4-Dec-15							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
MK	EPE	12	P-2014/316	3-Jul-07	905674	7-May-14	3-Jul-27	Granted
MK	EPE	11	P/EP-2014/2	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
MT	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
MT	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
MX	DIV	01	MX/A/2012/002225	3-Jul-07	330494	3-Jun-15	3-Jul-27	Granted
MX	PCT	01	MX/A/2008/016123	3-Jul-07	364479	19-Oct-12	3-Jul-27	Granted
MX	DIV	02	MX/A/2014/014529	3-Jul-07		3-Jul-27	Pending	TAKDE
NL	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
NL	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
NO	PCT	01	20090370	3-Jul-07		3-Jul-27	Published	TAKDE
NZ	DIV	02	603207	3-Jul-07	603207	21-Mar-14	3-Jul-27	Granted
NZ	DIV	01	594369	3-Jul-07	594369	28-Jan-14	3-Jul-27	Granted
NZ	PCT	01	573378	3-Jul-07	573378	9-Jul-12	3-Jul-27	Granted
PL	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
PL	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
PT	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
PT	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
RO	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
RO	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
RS	EPE	12	P-2014/0402	3-Jul-07	53461	7-May-14	3-Jul-27	Granted

11

71

Inventor:	1474							
Title:	Combination of Roflumilast with Statins/HMG-CCoA Reductase Inhibitors							
Status as of:	4-Dec-15							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
RS	EPE	11	P-13-0560	3-Jul-07	53084	30-Oct-13	3-Jul-27	Granted
RU	EAC	01	200900073	3-Jul-07	021461	30-Jun-15	3-Jul-27	Granted
SE	EPC	12	11164518.0-1464	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
SE	EPC	11	11164516.4-1464	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
SI	EPC	11	P200731395	3-Jul-07	2359826	30-Oct-13	3-Jul-27	Granted
SI	EPC	12	P200731492	3-Jul-07	2363130	7-May-14	3-Jul-27	Granted
SK	EPC	11	11164516.4-1464	3-Jul-07	E15743	30-Oct-13	3-Jul-27	Granted
SK	EPC	12	11164518.0-1464	3-Jul-07	E16684	7-May-14	3-Jul-27	Granted
TR	EPC	11	11164516.4-1464	3-Jul-07	TR2014/00867	30-Oct-13	3-Jul-27	Granted
TR	EPC	12	11164518.0-1464	3-Jul-07	TR2014/08540	7-May-14	3-Jul-27	Granted
UA	DIV	01	201111256	3-Jul-07	101556	13-Dec-12	3-Jul-27	Granted
UA	DIV	02	201212337	3-Jul-07	108422	26-Aug-14	3-Jul-27	Granted
UA	PCT	01	200900759	3-Jul-07	98466	25-May-12	3-Jul-27	Granted
US	CON	01	14719948	3-Jul-07		3-Jul-27	Pending	TAKDE
WO	ORD	01	PCT/EP2007/056688 3	3-Jul-07		3-Jul-27	National Phase	NYCO
ZA	PCT	01	2008/09905	3-Jul-07	2008/09905	25-Nov-09	3-Jul-27	Granted

Invention:	1630						
Title:	Treatment of COPD with Roflumilast in specific patient-populations						
Status as of:	4-Dec-15						
Owner:	TAKDE = Takeda GmbH						
Country	Case	Sub Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Owner/Co-Owner
US	ORD	01 13/216936	24-Aug-11			24-Aug-31	TAKDE

Invention:	B518							
Title:	Roflumilast basic Substance Patent							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
AT	SPC	01	SZ34/2010	5-Oct-10	SZ34/2010	3-Jul-14	2-Jul-19	Granted
BE	SPC	01	2010C1042	8-Dec-10	2010C1042	3-Jul-14	2-Jul-19	Granted
CH	SPC	01	C00706513/01	10-Jan-12	C0706513/01	2-Jul-14	1-Jul-19	Granted
CY	SPC	01	17330/1	29-Sep-10	CY2010015	3-Jul-14	2-Jul-19	Granted
CZ	SPC	01	SPC2010/178	19-Jul-10	290266/178	3-Jul-14	2-Jul-19	Granted
DE	SPC	01	122010000043.2	30-Sep-10	122010000043	3-Jul-14	2-Jul-19	Granted
DK	SPC	01	CA 2010 00028	23-Sep-10	CR 2010 00028	3-Jul-14	2-Jul-19	Granted
EP	PCT	00	94924713.4-2117	2-Jul-94	07065/3	15-May-02	2-Jul-14	EP APAG NoOpposition
ES	SPC	01	C 201000042	15-Dec-10	201000042	3-Jul-14	2-Jul-19	Granted
FI	SPC	01	C20100026	1-Nov-10	352	3-Jul-14	2-Jul-19	Granted
FR	SPC	01	10C0052	6-Dec-10	10C0052	3-Jul-14	1-Jul-19	Granted
GB	SPC	01	SPC/GB10/040	28-Oct-10	SPC/GB10/040	3-Jul-14	1-Jul-19	Granted
GR	SPC	01	20100800026	22-Sep-10	8000349	3-Jul-14	3-Jul-19	Granted
HU	SPC	01	S1000016	16-Sep-10	S0000118	3-Jul-14	2-Jul-19	Granted
IE	SPC	01	2010/031	23-Sep-10	2010/031	3-Jul-14	1-Jul-19	Granted
IT	SPC	01	UB2010CCP1183	26-Nov-10	001183	3-Jul-14	2-Jul-19	Granted
KR	PTE	01	10-2011-0077052	2-Aug-11	10-0331255	3-Jul-14	3-Jul-19	Granted
LU	SPC	01	911709	21-Jul-10	91109	3-Jul-14	2-Jul-19	Granted
LV	REG	01	P-03-48	13-May-03	13074	20-Mar-04	13-May-23	Granted
LV	SPC	01	C/LV2010/0010	21-Sep-10	C/LV2010/0010	14-May-23	5-Jul-25	Granted

Invention:	B518								
Title:	Roflumilast basic Substance Patent								
Status as of:	4-Dec-15								
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomborg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH								
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-Owner
NL	SPC	01	300462	29-Oct-10	300462	3-Jul-14	1-Jul-19	Granted	TAKDE
NO	SPC	01	20100118	30-Sep-10	20100118	3-Jul-14	2-Jul-19	Granted	TAKDE
PL	SPC	01	0164/0178314	29-Nov-10	178314	3-Jul-14	2-Jul-19	Granted	NYCO
PT	SPC	01	426	6-Dec-10	426	3-Jul-14	2-Jul-19	Granted	TAKDE
RU	PTE	01	96102569	30-Jan-12	2137754	3-Jul-14	2-Jul-19	Granted	TAKDE
SE	SPC	01	1090034-8	17-Sep-10	1090034-8	3-Jul-14	2-Jul-19	Granted	NYCO
SI	SPC	01	C201040013	23-Nov-10	201040013	3-Jul-14	2-Jul-19	Granted	TAKDE
SK	SPC	01	5013-2010	23-Nov-10	96	3-Jul-14	3-Jul-19	Granted	TAKDE
US	PTE	01	PTE08/564322	14-Apr-11	5712298	16-Jun-15	27-Jan-20	Granted	TAKDE
WO	ORD	00	PCT/EP94/02169	2-Jul-94				National Phase	BYK

Invention:	B619							
Title:	Combination of PDE inhibitors with AC Agonists							
Status as of:	4-Dec-15							
Owner:	BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status
AL	EPE	00	AL/P/08/02620	24-Feb-98	02593	20-Feb-08	24-Feb-18	Granted
AT	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
BE	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
CH	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
CY	REG	01	CY200900008	24-Feb-98	CY2607	20-Feb-08	24-Feb-18	Granted
DE	EPC	00	98913584.3-2123	24-Feb-98	59814173.1-08	20-Feb-08	24-Feb-18	Granted
DK	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
EP	PCT	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	EPI NoOpposition
ES	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
FI	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
FR	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
GB	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
GR	EPC	00	98913584.3-2123	24-Feb-98	3065139	20-Feb-08	24-Feb-18	Granted
IE	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
IT	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
LT	EPE	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
LU	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
LV	EPE	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
MC	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted
MK	EPE	00	98913584.3-2123	24-Feb-98	902846	20-Feb-08	24-Feb-18	Granted

Invention:	B619								
Title:	Combination of PDE inhibitors with AC Agonists								
Status as of:	4-Dec-15								
Owner:	BYK = Byk Gulden Lomborg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH								
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-owner
NL	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted	TAKDE
PT	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted	TAKDE
RO	EPE	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted	TAKDE
SE	EPC	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted	NYCO
SI	EPE	00	98913584.3-2123	24-Feb-98	0975347	20-Feb-08	24-Feb-18	Granted	TAKDE
US	CON	01	104437005	24-Feb-98	7056836	6-Jun-06	24-Feb-18	Granted	TAKDE
US	CIP	01	10049999	11-Aug-00	6624181	23-Sep-03	11-Aug-20	Granted	TAKDE
US	PCT	00	09367850	24-Feb-98	6333354	25-Dec-01	24-Feb-18	Granted	TAKDE
WO	ORD	00	PCT/EP98/01047	24-Feb-98				National Phase	BYK

Invention:	B701						
Title:	Combination of PDE inhibitors with β 2-Sympathomimetics						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, BYK = BYK Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
AL	EPE	01	AL/P/06/01931	11-Aug-00	01931	22-Mar-06	11-Aug-20
AT	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20
AU	PCT	01	67016/00	11-Aug-00	777012	20-Jan-05	11-Aug-20
BE	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20
BR	PCT	01	PI0013478-3	11-Aug-00			11-Aug-20
BY	EAC	01	200200208	11-Aug-00	0066385	24-Feb-06	11-Aug-20
CA	PCT	01	2381802	11-Aug-00	2381802	7-Dec-10	11-Aug-20
CH	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20
CN	PCT	01	00811849.3	11-Aug-00	ZL00811849.3	25-May-05	11-Aug-20
CY	EPC	01	CY06/1100794	11-Aug-00	CY1104883	22-Mar-06	11-Aug-20
CZ	PCT	01	PV2002-641	11-Aug-00	3028882	23-Nov-11	11-Aug-20
DE	EPC	01	00954625.0-2405	11-Aug-00	60025855.1-08	22-Mar-06	11-Aug-20
DK	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20
EA	PCT	01	200200208	11-Aug-00	0066385	24-Feb-06	11-Aug-20
EP	PCT	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20
ES	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20
FI	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20
FR	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20
GB	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20
GR	EPC	01	00954625.0-2405	11-Aug-00	3057785	22-Mar-06	11-Aug-20

Invention:	B701							
Title:	Combination of PDE inhibitors with B2-Sympathomimetics							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
HK	REG	01	02108936.8	11-Aug-00	1047244B	27-Oct-06	11-Aug-20	Granted
HR	PCT	01	P20020158A	11-Aug-00	P20020158	27-Jul-07	11-Aug-20	Granted
HU	PCT	01	P0203098	11-Aug-00	229439	22-Nov-13	11-Aug-20	Granted
ID	PCT	01	W00-2002.00430	11-Aug-00	ID0015194	20-Jan-05	11-Aug-20	Granted
IE	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
IL	PCT	01	147688	11-Aug-00	147688	21-Dec-07	11-Aug-20	Granted
IN	PCT	01	2002/00066/MUM	11-Aug-00	206328	24-Apr-07	11-Aug-20	Granted
IT	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
JP	PCT	01	2001-518088	11-Aug-00	5038568	13-Jul-12	11-Aug-20	Granted
KR	PCT	01	10-2002-7002143	11-Aug-00	10-0701904	26-Mar-07	11-Aug-20	Granted
LT	EPE	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
LJ	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
LV	EPE	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
MC	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
MK	EPE	01	00954625.0-2405	11-Aug-00	902248	22-Mar-06	11-Aug-20	Granted
MX	PCT	01	PA/A/2002/001830	11-Aug-00	246925	2-Jul-07	11-Aug-20	Granted
NL	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
NO	PCT	01	20020815	11-Aug-00	328340	1-Feb-10	11-Aug-20	Granted
NZ	PCT	01	517166	11-Aug-00	517166	10-May-04	11-Aug-20	Granted
PL	PCT	01	P356252	11-Aug-00	200923	27-Jun-08	11-Aug-20	Granted

Invention:	B701							
Title:	Combination of PDE inhibitors with β2-Sympathomimetics							
Status as of:	4-Dec-15							
Owner:	APAG = ALTANA Pharma AG, BYK = Byk Gulden Lomberg GmbH, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
PT	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
RO	EPE	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
RU	EAC	01	200200208	11-Aug-00	006685	24-Feb-06	11-Aug-20	Granted
SE	EPC	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
SI	EPE	01	00954625.0-2405	11-Aug-00	1212089	22-Mar-06	11-Aug-20	Granted
SK	PCT	01	PP0255-2002	11-Aug-00	287231	4-Feb-10	11-Aug-20	Granted
TR	PCT	01	2002/01317	11-Aug-00	TR200201317	21-Apr-11	11-Aug-20	Granted
WO	ORD	01	PCT/EP0007852	11-Aug-00			11-Aug-20	National Phase
ZA	PCT	01	2002/1389	11-Aug-00	2002/1389	27-Nov-02	11-Aug-20	Granted

Invention:	1057						
Title:	Prilled active Compound Compositions in Particular Roflumilast						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
CH	EPC	01	01999359.1-1219	6-Dec-01	1341527	10-Aug-11	6-Dec-21
DE	ORD	01	10061137.0-41	7-Dec-00			7-Dec-20
DE	EPC	01	01999359.1-1219	6-Dec-01	60145138.4	10-Aug-11	6-Dec-21
EP	PCT	01	01999359.1-1219	6-Dec-01	1341527	10-Aug-11	6-Dec-21
FR	EPC	01	01999359.1-1219	6-Dec-01	1341527	10-Aug-11	6-Dec-21
GB	EPC	01	01999359.1-1219	6-Dec-01	1341527	10-Aug-11	6-Dec-21
JP	PCT	01	2002-547479	6-Dec-01	4950409	16-Mar-12	6-Dec-21
US	PCT	01	10433398	6-Dec-01	71175854	13-Feb-07	5-Feb-23
US	CON	01	11/642621	6-Dec-01	7951398	31-May-11	31-May-20
WO	ORD	01	PCT/EP01/14307	6-Dec-01		6-Dec-21	National Phase
							APAG

Invention:	1087						
Title:	Avoidance of NSAIDS induced Ulceras by PDE4 Inhibitors						
Status as of:	15-Feb-16						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
AL	EPE	01	AL/P/07/2278	17-Sep-02	2277	28-Feb-07	17-Sep-22
CH	EPC	01	02772313.9-1216	17-Sep-02	1429807	28-Feb-07	17-Sep-22
DE	EPC	01	02772313.9-1216	17-Sep-02	60218497.5-08	28-Feb-07	17-Sep-22
EP	PCT	01	02772313.9-1216	17-Sep-02	1429807	28-Feb-07	17-Sep-22
FR	EPC	01	02772313.9-1216	17-Sep-02	1429807	28-Feb-07	17-Sep-22
GB	EPC	01	02772313.9-1216	17-Sep-02	1429807	28-Feb-07	17-Sep-22
JP	PCT	01	2003-528583	17-Sep-02	45883998	17-Sep-10	17-Sep-22
US	DIV	01	12/003129	17-Sep-02	8242146	14-Aug-12	6-Jan-26
WO	ORD	01	PCT/EP02/10424	17-Sep-02		17-Sep-22	National Phase
							APAG

Invention:	1105						
Title:	Deinol Administration Forms for Roflumilast						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
CH	EPC	01	03755048.0-2123	27-May-03	1511516	17-Dec-08	27-May-23
DE	EPC	01	03755048.0-2123	27-May-03	60325354.7-08	17-Dec-08	27-May-23
EP	DIV	11	08166780.0-1455	27-May-03			27-May-23
EP	PCT	01	03755048.0-2123	27-May-03	1511516	17-Dec-08	27-May-23
FR	EPC	01	03755048.0-2123	27-May-03	1511516	17-Dec-08	27-May-23
GB	EPC	01	03755048.0-2123	27-May-03	1511516	17-Dec-08	27-May-23
JP	DIV	01	2012-154020	27-May-03	56832538	23-Jan-15	27-May-23
JP	PCT	01	2004-506857	27-May-03	5652983	28-Nov-14	27-May-23
US	CON	02	14/075035	27-May-03		27-May-23	Pending
WO	ORD	01	PCT/EP03/05524	27-May-03		27-May-23	National Phase
							APAG

11

Invention:	1119						
Title:	PDE4-inhibitors for the Treatment of Diabetes Mellitus						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, TAKDE = Takeda GmbH						
Country	Case	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date
US	PCT	01	10/570622	2-Sep-04	7776893	17-Aug-10	10-Jul-25
WO	ORD	01	PCT/EP2004/052005	2-Sep-04			2-Sep-24
							National Phase
							APAG

Invention:	1194						
Title:	Rofumilast for the Treatment of Ophthalmological Diseases						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
AT	EPC	01	03730122	27-May-03	E485821	27-Oct-10	27-May-23
AU	PCT	01	2003240719	27-May-03	2003240719	25-Mar-10	27-May-23
BE	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
CA	PCT	01	2486910	27-May-03	2486910	29-Nov-11	27-May-23
CH	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
CN	PCT	01	03812094.1	27-May-03	03812094.1	27-May-09	27-May-23
DE	EPC	01	03730122.3-2123	27-May-03	60334692.8-08	27-Oct-10	27-May-23
DK	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
EP	PCT	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
ES	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
FR	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
GB	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
HK	REG	01	05111628.2	27-May-03	1079445	31-Dec-09	27-May-23
IL	PCT	01	165065	27-May-03	165065	1-Mar-11	27-May-23
IN	PCT	01	2004/005995/MUJMNIP	27-May-03	225301	6-Nov-08	27-May-23
IT	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
MX	PCT	01	PA/A/2004/011612	27-May-03	284863	18-Mar-11	27-May-23
NL	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
NO	PCT	01	20045656	27-May-03	333916	14-Jul-14	27-May-23
NZ	PCT	01	537308	27-May-03	537308	7-Jan-10	27-May-23

Invention:	1194						
Title:	Roflumilast for the Treatment of Ophthalmological Diseases						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
PL	PCT	01	P372082	27-May-03	211870	12-Jan-12	27-May-23
PT	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
SE	EPC	01	03730122.3-2123	27-May-03	1511481	27-Oct-10	27-May-23
TR	EPC	01	03730122.3-2123	27-May-03	TR201100475	27-Oct-10	27-May-23
WO	ORD	01	PCT/EP03/05536	27-May-03		27-May-23	National Phase
							APAG

Invention:	1291						
Title:	Roflumilast Solution as Administration Form						
Status as of:	4-Dec-15						
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
CH	EPC	01	05794694.9-2123	21-Sep-05	17966688	17-Sep-08	21-Sep-25
DE	EPC	01	05794694.9-2123	21-Sep-05	17966688	17-Sep-08	21-Sep-25
EP	PCT	01	05794694.9-2123	21-Sep-05	17966688	17-Sep-08	21-Sep-25
FR	EPC	01	05794694.9-2123	21-Sep-05	17966688	17-Sep-08	21-Sep-25
GB	EPC	01	05794694.9-2123	21-Sep-05	17966688	17-Sep-08	21-Sep-25
JP	PCT	01	2007-531767	21-Sep-05	5044404	20-Jul-12	21-Sep-25
US	PCT	01	11/662887	21-Sep-05	9205044	8-Dec-15	21-Sep-25
WO	ORD	01	PCT/EP2005/054723	21-Sep-05		21-Sep-25	National Phase APAG

Invention:	1331							
Title:	Roflumilast Dosage Form which is Taste Masked							
Status as of:	4-Dec-15							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
CH	EPC	01	06725035.7-1455	14-Mar-06	1861074	24-Apr-13	14-Mar-26	Granted
CH	EPC	11	10176091.6-1455	14-Mar-06	2258350	24-Dec-14	14-Mar-26	Granted
DE	EPC	11	10176091.6-1455	14-Mar-06	602006044131 ²	24-Dec-14	14-Mar-26	Granted
DE	EPC	01	06725035.7-1455	14-Mar-06	602006035877 ⁶	24-Apr-13	14-Mar-26	Granted
EP	PCT	01	06725035.7 - 1455	14-Mar-06	1861074	24-Apr-13	14-Mar-26	EP
EP	DIV	11	10176091.6-1455	14-Mar-06	2258350	24-Dec-14	14-Mar-26	EP NoOpposition
FR	EPC	01	06725035.7-1455	14-Mar-06	1861074	24-Apr-13	14-Mar-26	Granted
FR	EPC	11	10176091.6-1455	14-Mar-06	2258350	24-Dec-14	14-Mar-26	Granted
GB	EPC	11	10176091.6-1455	14-Mar-06	2258350	24-Dec-14	14-Mar-26	Granted
GB	EPC	01	06725035.7-1455	14-Mar-06	1861074	24-Apr-13	14-Mar-26	Granted
JP	PCT	01	2008-501285	14-Mar-06	5383183	11-Oct-13	14-Mar-26	Granted
US	PCT	01	11985837	14-Mar-06	8663694	4-Mar-14	12-Oct-29	Granted
WO	ORD	01	PCT/EP2006/06067 ⁹	14-Mar-06			14-Mar-26	National Phase

Invention:	1380						
Title:	Roflumilast for the Treatment of Diabetes Mellitus Type II						
Status as of:	15-Feb-16						
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH						

Country	Case Type	Sub Case	Application Number	Filing Date	Patient Number	Issue Date	Expiry Date	Status	Owner/Co-Owner
US	PCT	01	11/885450	3-Mar-06	8017633	13-Sep-11	9-Mar-28	Granted	TAKDE
US	CON	01	131179895	3-Mar-06	8541456	24-Sep-13	3-Mar-26	Granted	TAKDE
WO	ORD	01	PCT/EP2006/06041	3-Mar-06	8		3-Mar-26	National Phase	NYCO

Invention	B597	Title:	Lung surfactant (lissupultide) + Roflumilast	Status as of:	01-Mar-2016	Owner:	BYK = BYK Gulden Lomberg, APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH		
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-Owner
AL	EPE	01	AL/P/06/02089	14-Feb-98	02089	16-Aug-06	14-Feb-18	Granted	TAKDE
AT	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	NYCO
AU	PCT	00	64973/98	14-Feb-98	734122	20-Sep-01	14-Feb-18	Granted	TAKDE
BE	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE
BR	PCT	00	P19807399.0	14-Feb-98	P19807399-0	19-Apr-11	19-Apr-21	Granted	TAKDE
BY	EAC	0J	199900645	14-Feb-98	001758	27-Aug-01	14-Feb-18	Granted	TAKDE
CA	PCT	00	2276429	14-Feb-98	2276429	19-Jun-07	14-Feb-18	Granted	TAKDE
CH	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE
CN	PCT	00	96802597.3	14-Feb-98	ZL96802597.3	08-Oct-03	14-Feb-18	Granted	TAKDE
CZ	PCT	00	PV1999-2914	14-Feb-98	293871	14-Jun-04	14-Feb-18	Granted	TAKDE
DE	EPC	01	96910670.3	14-Feb-98	69835594-6-08	16-Aug-06	14-Feb-18	Granted	TAKDE
DK	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE
EA	RCT	00	199900645	14-Feb-98	001758	27-Aug-01	14-Feb-18	National Phase	NYCO
EE	PCT	00	P199800279	14-Feb-98	04094	15-Aug-03	14-Feb-18	Granted	TAKDE
EP	PCT	01	98910670-3-2123	14-Feb-98	0977577	16-Aug-06	14-Feb-18	EP	APAG
ES	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE
FI	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE
FR	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE
GB	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE

Invention:	B597									
Title:	Lung surfactant (Lusupultide) + Roflumilast									
Status as of:	01-Mar-2016									
Owner:	BYK = Byk Gulden Lomborg, APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH									
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-Owner	
GR	EPC	01	98910670.3	14-Feb-98	3059745	16-Aug-06	14-Feb-18	Granted	TAKDE	
HK	REG	01	00105462.8	14-Feb-98	1026145	02-Jul-04	14-Feb-18	Granted	TAKDE	
HU	PCT	00	P0001043	14-Feb-98	227520	28-Feb-12	14-Feb-18	Granted	TAKDE	
IE	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE	
IL	PCT	00	130658	14-Feb-98	130658	25-Oct-04	14-Feb-18	Granted	TAKDE	
IT	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE	
JP	PCT	00	1998-535366	14-Feb-98	4763104	17-Jun-11	14-Feb-18	Granted	TAKDE	
KR	PCT	00	10-1999-7007400	14-Feb-98	10-0640025	24-Oct-06	14-Feb-18	Granted	TAKDE	
LT	EPE	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE	
LU	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE	
LV	EPE	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE	
MC	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE	
MK	EPE	01	98910670.3	14-Feb-98	902344	16-Aug-06	14-Feb-18	Granted	TAKDE	
MX	PCT	00	9907560	14-Feb-98	219627	30-Mar-04	14-Feb-18	Granted	TAKDE	
MX	DIV	01	PA/A/2003/010187	14-Feb-98	247841	06-Aug-08	14-Feb-18	Granted	TAKDE	
NL	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE	
NO	PCT	00	19993875	14-Feb-98	323594	11-Jun-07	14-Feb-18	Granted	TAKDE	
NZ	PCT	00	336569	14-Feb-98	336569	09-Aug-01	14-Feb-18	Granted	TAKDE	
PL	PCT	00	P335134	14-Feb-98	190775	15-May-05	14-Feb-18	Granted	NYCO	
PT	EPC	01	98910670.3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted	TAKDE	

Invention:	B597							
Title:	Lung surfactant (Lusupatide) + Roflumilast							
Status as of:	01-Mar-2016							
Owner:	BYK = Byk Gulden Lomborg, APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
RO	EPE	01	98910670 3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted
RU	EAC	01	199800645	14-Feb-98	0017558	27-Aug-01	14-Feb-18	Granted
SE	EPC	01	98910670 3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted
SG	PCT	00	9902879-7	14-Feb-98	66117	21-Aug-01	14-Feb-18	Granted
SI	EPE	01	98910670 3	14-Feb-98	0977577	16-Aug-06	14-Feb-18	Granted
TR	PCT	00	1999/01772	14-Feb-98	1999/01772	23-Feb-04	14-Feb-18	Granted
UA	PCT	00	99084689	14-Feb-98	50808	15-Nov-02	14-Feb-18	Granted
US	DIV	01	10/096258	14-Feb-98	6998410	14-Feb-06	01-Nov-19	Granted
US	PCT	01	09/369455	14-Feb-98	6436970	20-Aug-02	14-Feb-18	Granted
WO	ORD	01	PCT/EP98/00847	14-Feb-98			National Phase	BYK

Pipeline Product Patents

Invention:	1595							
Title:	PDE4-5 Hybrids							
Status as of:	4-Dec-15							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
BR	PCT	01	BR112012014058-2	15-Dec-10			15-Dec-30	Published
CA	PCT	01	2784013	15-Dec-10			15-Dec-30	Examination
CH	EPC	01	10790569.7-1452	15-Dec-10	2513119	25-Jun-14	15-Dec-30	Granted
CN	PCT	01	201080057293.7	15-Dec-10	ZL201080057293.7	26-Nov-14	15-Dec-30	Granted
DE	EPC	01	10790569.7-1452	15-Dec-10	602010017077.2	25-Jun-14	15-Dec-30	Granted
EA	PCT	01	201200891	15-Dec-10			15-Dec-30	Published
EP	PCT	01	10790569.7-1452	15-Dec-10	2513119	25-Jun-14	15-Dec-30	EP
EP	DIV	11	14164018.5-1452	15-Dec-10			15-Dec-30	NoOpposition
ES	EPC	01	10790569.7-1452	15-Dec-10	2505290	25-Jun-14	15-Dec-30	Granted
FR	EPC	01	10790569.7-1452	15-Dec-10	2513119	25-Jun-14	15-Dec-30	Granted
GB	EPC	01	10790569.7-1452	15-Dec-10	2513119	25-Jun-14	15-Dec-30	Granted
IN	PCT	01	1721MUMNP/2012	15-Dec-10			15-Dec-30	Examination
IT	EPC	01	10790569.7-1452	15-Dec-10	2513119	25-Jun-14	15-Dec-30	Granted
JP	PCT	01	2012-543701	15-Dec-10	5645961	14-Nov-14	15-Dec-30	Granted
US	PCT	01	13515214	15-Dec-10	901875	28-Apr-15	23-Dec-31	Granted
WO	ORD	01	PCT/EP2010/0697	15-Dec-10			15-Dec-30	National Phase

04

94

Invention:	1598							
Title:	Methylpyrrolopyrimidinecarboxamides							
Status as of:	4-Dec-15							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
AE	PCT	01	183/2012	24-Aug-10			24-Aug-30	Examination
AR	ORD	01	100103064	23-Aug-10			23-Aug-30	Examination
AU	PCT	01	2010288550	24-Aug-10	2010288550	14-May-15	24-Aug-30	Granted
BR	PCT	01	112012003616-5	24-Aug-10			24-Aug-30	Published
CA	PCT	01	2771938	24-Aug-10			24-Aug-30	Published
CH	EPC	01	10744949.8-2101	24-Aug-10	2470536	12-Nov-14	24-Aug-30	Granted
CL	PCT	01	00271-2012	24-Aug-10	51291	21-Oct-15	24-Aug-30	Granted
CN	PCT	01	201080046838.4	24-Aug-10	ZL201030046833	5-Aug-15	24-Aug-30	Granted
CO	PCT	01	12-018.550	24-Aug-10			24-Aug-30	Examination
DE	EPC	01	10744949.8-2101	24-Aug-10	602010020160.	12-Nov-14	24-Aug-30	Granted
			0					
EA	PCT	01	201200322	24-Aug-10	021103	30-Apr-15	24-Aug-30	National Phase
EC	PCT	01	SP-12-11678	24-Aug-10			24-Aug-30	Published
EG	PCT	01	286/2012	24-Aug-10			24-Aug-30	Published
EP	PCT	01	10744949.8-2101	24-Aug-10	2470536	12-Nov-14	24-Aug-30	EP
								NoOpposition
ES	EPC	01	10744949.8-2101	24-Aug-10	2470536	12-Nov-14	24-Aug-30	Granted
FR	EPC	01	10744949.8-2101	24-Aug-10	2470536	12-Nov-14	24-Aug-30	Granted
GB	EPC	01	10744949.8-2101	24-Aug-10	2470536	12-Nov-14	24-Aug-30	Granted
HK	REG	01	12110218.1	24-Aug-10			24-Aug-30	Published

Invention:	1598							
Title:	Methylpyrrolopyrimidinecarboxamides							
Status as of:	4-Dec-15							
Owner:	NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
ID	PCT	01	W00-2012.00708	24-Aug-10			24-Aug-30	Examination
IL	PCT	01	218126	24-Aug-10			24-Aug-30	Pending
IN	PCT	01	692/MUMNP/2012	24-Aug-10			24-Aug-30	Published
IT	EPC	01	10744949.8-2101	24-Aug-10	2470536	12-Nov-14	24-Aug-30	Granted
JP	PCT	01	2012-526038	24-Aug-10	5791606	14-Aug-15	24-Aug-30	Granted
KR	PCT	01	10-2012-7006983	24-Aug-10			24-Aug-30	Examination
MX	PCT	01	MX/A/2012/002432	24-Aug-10	322028	16-Jul-14	24-Aug-30	Granted
MY	PCT	01	PI2012000701	24-Aug-10			24-Aug-30	Examination
NZ	PCT	01	598777	24-Aug-10	598777	28-Jan-14	24-Aug-30	Granted
PE	PCT	01	214/2012	24-Aug-10			24-Aug-30	Published
PH	PCT	01	1-2012-500337	24-Aug-10	1-2012-500337	2-Jul-15	24-Aug-30	Granted
PK	ORD	01	733/2010	23-Aug-10			23-Aug-30	Pending
RU	EAC	01	201200322	24-Aug-10	021103	30-Apr-15	24-Aug-30	Granted
SG	PCT	01	201201121-9	24-Aug-10	178481	1-Oct-14	24-Aug-30	Granted
TN	PCT	01	TN2012/0034	24-Aug-10	22631	22-Nov-13	24-Aug-30	Granted
TW	ORD	01	099128511	25-Aug-10	1471327	1-Feb-15	24-Aug-30	Granted
UA	PCT	01	201203246	24-Aug-10	106628	25-Sep-14	24-Aug-30	Granted
US	PCT	01	13/390640	24-Aug-10	8927557	6-Jan-15	6-Nov-30	Granted
US	CON	01	14/547938	24-Aug-10			24-Aug-30	Pending
VN	PCT	01	1-2012-00803	24-Aug-10			24-Aug-30	Published

/1

Invention:	1598						
Title:	Methylpyrrolopyrimidinecarboxamides						
Status as of:	4-Dec-15						
Owner:	NYCO = Nycomed GmbH; TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
WO	ORD	01	PCT/EP2010/062329	24-Aug-10		24-Aug-30	National Phase
ZA	PCT	01	2012/00616	24-Aug-10	2012/00616	31-Oct-12	Granted
							TAKDE

PATENT
REEL: 040057 FRAME: 0152

Invention	1620	PDE4-5 Hybrides II							
Title:									
Status as of:	4-Dec-15								
Owner:	TAKDE = Takeda GmbH								
Country	Case Type	Sub Case	AppliNumber	FilDate	PatNumber	IssDate	ExpDate	Status	fid_Owner
CH	EPC	01	12729458.5-1462	12-Jun-12	2721036	22-Jul-15	12-Jun-32	Granted	TAKDE
DE	EPC	01	12729458.5-1462	12-Jun-12	602012008976.	22-Jul-15	12-Jun-32	Granted	TAKDE
EP	PCT	01	12729458.5-1462	12-Jun-12	2721036	22-Jul-15	12-Jun-32	Granted	TAKDE
FR	EPC	01	12729458.5-1462	12-Jun-12	2721036	22-Jul-15	12-Jun-32	Granted	TAKDE
GB	EPC	01	12729458.5-1462	12-Jun-12	2721036	22-Jul-15	12-Jun-32	Granted	TAKDE
JP	PCT	01	2014-515156	12-Jun-12			12-Jun-32	Examination	TAKDE
US	PCT	01	14/124446	12-Jun-12			12-Jun-32	Published	TAKDE
WO	ORD	01	PCT/EP2012/0610	12-Jun-12			12-Jun-32	National Phase	TAKDE

Invention:	1625						
Title:	PDE 4/5 hybrides Phthalazinone-Pyrimidine-Derivatives						
Status as of:	14-Apr-16						
Owner:	TAKDE = Takeda GmbH						
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date
BR	PCT	01	BR112013031791-4	12-Jun-12		12-Jun-32	Published
CA	PCT	01	2837248	12-Jun-12		12-Jun-32	Published
CH	EPC	01	12728453.7-1451	12-Jun-12	2721030	16-Dec-15	Granted
CN	PCT	01	201280028413.X	12-Jun-12		12-Jun-32	Examination
DE	EPC	01	12728453.7-1451	12-Jun-12	602012013135.7	16-Dec-15	Granted
EA	PCT	01	201400001	12-Jun-12		12-Jun-32	Published
EP	PCT	01	12728453.7-1451	12-Jun-12	2721030	16-Dec-15	Granted
ES	EPC	01	12728453.7-1451	12-Jun-12	2721030	16-Dec-15	Granted
FR	EPC	01	12728453.7-1451	12-Jun-12	2721030	16-Dec-15	Granted
GB	EPC	01	12728453.7-1451	12-Jun-12	2721030	16-Dec-15	Granted
IN	PCT	01	43/MUMNP/2014	12-Jun-12		12-Jun-32	Examination
IT	EPC	01	12728453.7-1451	12-Jun-12	2721030	16-Dec-15	Granted
JP	PCT	01	2014-515155	12-Jun-12		12-Jun-32	Examination
US	CON	01	14/958141	12-Jun-12		12-Jun-32	Published
WO	ORD	01	PCT/EP2012/061084	12-Jun-12		12-Jun-32	National Phase

Unfiled Inventions	
Status as of	18-Feb-16
Owner:	TAKDE = Takeda GmbH
Invention	Title
1716	Inhaled PDE4 inhibitors (NYC 493650)

General Inhalation Patents

Invention:	1235							
Title:	Compliance Monitor and Method							
Status as of:	01-Mar-2016							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
AU	PCT	01	2004273627	22-Sep-04	2004273627	02-Dec-10	22-Sep-24	Granted
CA	PCT	01	2539375	22-Sep-04	2539375	12-Feb-13	22-Sep-24	Granted
DE	EPC	01	04787185.0-2320	22-Sep-04	7	602004038538.	11-Jul-12	22-Sep-24
EP	PCT	01	04787185.0-2320	22-Sep-04	1670533	11-Jul-12	22-Sep-24	EP
ES	EPC	01	04787185.0-2320	22-Sep-04	1670533	11-Jul-12	22-Sep-24	No Opposition
FR	EPC	01	04787185.0-2320	22-Sep-04	1670533	11-Jul-12	22-Sep-24	Granted
GB	EPC	01	04787185.0-2320	22-Sep-04	1670533	11-Jul-12	22-Sep-24	Granted
GB	ORD	01	0322381.7	24-Sep-03	2406283	05-Apr-06	24-Sep-23	Granted
IT	EPC	01	04787185.0-2320	22-Sep-04	48	5020129020852	11-Jul-12	22-Sep-24
JP	PCT	01	2006-527413	22-Sep-04	46662936	14-Jan-11	22-Sep-24	Granted
US	PCT	01	10/572,316	22-Sep-04	8464707	18-Jun-13	02-Feb-27	Granted
WO	ORD	01	PCT/EP2004/052265	22-Sep-04			22-Sep-24	National Phase APAG

//

Schedule 2

Assigned Registered Designs

Designs	Owner	Design Date	Country	Internal Description	Locarno Class	Product	Status	Appl. No.	Filing Date	Req. No.	Req. Date	Exp. Date
		Status as of	2016-03-08									
	Takeda GmbH, Germany											
ALVESCO / ZETONNA	AVIID	EM	European Community	Inhalator	2404	Inhalator	Registered	000873914	6. Feb. 08	000873914	6. Feb. 08	6. Feb. 33
ALVESCO / ZETONNA	AVIID	US	United States of America	Inhaler	2902	Inhaler	Registered	29/283277	9. Aug. 07	D582544S	9. Dec. 08	9. Dec. 22
DAXAS	DSRI D	EM	European Community	launch pivotal study	3200	Logo; Zeichnung	Registered	001105894	16. Mar. 09	001105894	16. Mar. 09	16. Mar. 34
DAXAS	DTDI D	AR	Argentina	DAXAS D-Shape Tablet	n/a	tablet	Registered	76909	10. Aug. 07	76909	10. Aug. 07	10. Aug. 22
DAXAS	DTDI D	BR	Brazil	DAXAS D-Shape Tablet	n/a	tablet	Registered	D16702312-6	25. Jul. 07	D16702312-6	29. Jan. 08	25. Jul. 32
DAXAS	DTDI D	CA	Canada	DAXAS D-Shape Tablet	n/a	tablet	Registered	119901	14. Mar. 07	119901	17. Mar. 08	17. Mar. 18
DAXAS	DTDI D	EM	European Community	Daxas D-Shape Tablette Fairfotos	2801	Tabletten [pharmazeutische]	Registered	000670062-0001	12. Feb. 07	000670062-0001	12. Feb. 07	12. Feb. 32
DAXAS	DTDI D	EM	European Community	Daxas D-Shape Tablette Zeichnungen	2801	Tabletten [pharmazeutische]	Registered	000670062-0002	12. Feb. 07	000670062-0002	12. Feb. 07	12. Feb. 32
DAXAS	DTDI D	MX	Mexico	Tablet	0101	tablet	Registered	MX/F2007/01657	9. Aug. 07	25560	15. Apr. 08	9. Aug. 22

Designs												
Status as of	2015-02-28											
Owner	Takeda GmbH Germany											
Design	Code	Copy Code	Country	Internal Description	Locano Class	Product	Status	Appl. No.	Filing Date	Reg. No.	Reg. Date	Exp. Date
DAXAS	DTD1 D	US	United States of America	DAXAS D-Shape Tablette	2801	tablet	Registered	29/282864	31. Jul. 07	D580547S	11. Nov. 08	11. Nov. 22

Schedule 3

3M Business IPR

Part A: Solely Owned 3M Business Patents

Invention:	B641									
Title:	Ciclesonide Aerosole MDI formulation									
Status as of:	25-Feb-16									
Owner:	NYCC = Nycomed GmbH, TAKDE = Takeda GmbH									
Country	Case Type	Case Number	Application Case	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-Owner	
BA	PCT	00	BAP99511A	18-May-98	BAP99511	27-Apr-09	18-May-18	Granted	TAKDE	
BG	SPC	01	09/001	09-Jan-09	09/001	19-May-18	16-Apr-19	Granted	TAKDE	
BG	PCT	00	103902	18-May-98	64268	03-Sep-04	18-May-18	Granted	TAKDE	
BR	PCT	00	P19809448-3	18-May-98			18-May-18	Appealed	TAKDE	
BY	EAC	OJ	199900991	18-May-98	002381	25-Apr-02	18-May-18	Granted	TAKDE	
BY	PTE	OJ	002381	13-Mar-12	002381	19-May-18	18-May-23	Granted	TAKDE	
EA	PCT	00	199900991	18-May-98	002381	25-Apr-02	18-May-18	National Phase	NYCO	
KS	REG	OJ	591	18-May-98	123	10-Jan-11	18-May-18	Granted	TAKDE	
ME	REG	OJ	P-598/99	18-May-98	01631PP	16-Apr-14	18-May-18	Granted	TAKDE	
RS	PCT	OJ	P-598/99	18-May-98	49628	03-Aug-07	18-May-18	Granted	TAKDE	
RU	EAC	OJ	199900991	18-May-98	002381	25-Apr-02	18-May-18	Granted	TAKDE	
SG	PCT	OJ	9905333-0	18-May-98	68804	06-Mar-02	18-May-18	Granted	TAKDE	
SK	SPC	OJ	PDO0005-2005	08-Jul-05	DO36	19-May-18	16-Apr-19	Granted	TAKDE	
SK	PCT	OJ	PP1576199	18-May-98	283930	04-May-04	18-May-18	Granted	TAKDE	

Invention:	B641							
Title:	Ciclesonide Aerosole MDI formulation							
Status as of:	25-Feb-16							
Owner:	NYCO = Nycomed GmbH; TAKDE = Takeda GmbH							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
TR	PCT	00	1999/02863	18-May-98	TR1999/02863	21-Sep-00	18-May-18	Oppo
UA	PCT	00	99116244	18-May-98	58351	15-Aug-03	18-May-18	Granted

Part B: Co-Owned Business IPR

Invention:	B641							
Title:	Ciclesonide Aerosole MDI formulation							
Status as of:	26-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH, 3MUS = 3M and Affiliates							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
AL	EPE	01	AL/P/03/00773	18-May-98	00773	30-Jul-03	18-May-18	Granted
AT	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
AU	PTE	01	74962/98	03-Jun-04	726835	19-May-18	24-Feb-19	Granted
AU	PCT	00	74962/98	18-May-98	726835	08-Mar-01	18-May-18	Granted
BE	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
CA	PCT	00	2290521	18-May-98	2290521	10-Oct-06	18-May-18	Granted
CH	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
CL	REG	02	1326/2004	13-May-98		13-May-18	Examination	TAKDE/3MUS
CN	PCT	00	98805261.X	18-May-98	98805261.X	12-May-04	18-May-18	Granted
CZ	SPC	01	SPC/CZ2007/119	27-Dec-07	298353/119	19-May-18	16-Apr-19	Granted
CZ	PCT	00	PV199-4124	18-May-98	298233	28-Jun-07	18-May-18	Granted
DE	EPC	0E	98922409.2	18-May-98	698168119-08	30-Jul-03	18-May-18	Granted
DK	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
DK	SPC	01	CA 2005 00036	07-Jul-05	CR 2005 00036	18-May-18	16-Apr-19	Granted
EP	PCT	00	98922409.2-2112	18-May-98	0983058	30-Jul-03	18-May-18	EP
ES	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
FR	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
GB	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted

Invention:	B641							
Title:	Ciclesonide Aerosole MDI formulation							
Status as of:	25-Feb-16							
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH, 3MUS = 3M and Affiliates							
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status
GR	EPC	0E	98922409.2	18-May-98	3046823	30-Jul-03	18-May-18	Granted
HK	REG	01	00105446.9	18-May-98	1027027	16-Jul-04	18-May-18	Granted
HU	PCT	00	P0002691	18-May-98	226694	21-May-09	18-May-18	Granted
HU	SPC	01	S0900014	18-Aug-09	S000094	18-May-18	17-Apr-19	Granted
IE	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
IE	SPC	01	SPC 2/2005	18-Jul-05	SPC 22/2005	18-May-18	15-Apr-19	Granted
IL	PCT	00	132738	18-May-98	132738	21-Sep-04	18-May-18	Granted
IT	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
JP	DIV	02	2014-187710	18-May-98		18-May-18	Published	NYCO/3MUS
KR	PCT	00	10-1999-7010773	18-May-98	10-0527643	03-Nov-05	18-May-18	Granted
KR	PTE	01	10-2007-0012702	20-Jul-07	10-0527643	19-May-18	04-Nov-19	Granted
LT	SPC	01	PA2005-006	15-Jul-05	C0983058	19-May-18	22-Mar-20	Granted
LT	EPE	01	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
LU	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
LV	EPE	01	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
LV	SPC	01	C/LV2005/0006/Z	07-Jun-05	C/LV2005/0006/Z	19-May-18	16-Apr-19	Granted
MC	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted
MK	EPE	01	98922409.2	18-May-98	901262	30-Jul-03	18-May-18	Granted
MX	PCT	00	9910646	18-May-98	264386	06-Feb-09	18-May-18	Granted
NL	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted

11

Invention:	B641								
Title:	Ciclesonide Aerosole MDI formulation								
Status as of:	25-Feb-16								
Owner:	APAG = ALTANA Pharma AG, NYCO = Nycomed GmbH, TAKDE = Takeda GmbH, 3MUS = 3M and Affiliates								
Country	Case Type	Sub Case	Application Number	Filing Date	Patent Number	Issue Date	Expiry Date	Status	Owner/Co-Owner
NO	SPC	01	2009024	26-Oct-09	2009024	19-May-18	16-Apr-19	Granted	TAKDE/3MUS
NO	PCT	00	19995667	18-May-98	327716	14-Sep-09	18-May-18	Granted	TAKDE/3MUS
NZ	PCT	00	500874	18-May-98	500874	10-Jan-02	18-May-18	Granted	TAKDE/3MUS
PL	PCT	00	P336885	18-May-98	191523	30-Jun-06	18-May-18	Granted	TAKDE/3MUS
PL	SPC	01	81/191523	18-Apr-06	191523	18-May-18	17-Mar-19	Granted	TAKDE/3MUS
PT	EPC	0E	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted	TAKDE/3MUS
RO	EPE	01	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted	TAKDE/3MUS
SE	SPC	01	0590022-0	13-Jun-05	0590022-0	19-May-18	15-Apr-19	Granted	TAKDE/3MUS
SE	EPC	0E	98922409.2	18-May-98	98922409.2	30-Jul-03	18-May-18	Granted	TAKDE/3MUS
SI	SPC	01	C-200540008	08-Jun-05	200540008	19-May-18	16-Apr-19	Granted	TAKDE/3MUS
SI	EPE	01	98922409.2	18-May-98	0983058	30-Jul-03	18-May-18	Granted	TAKDE/3MUS
US	ORD	01	09/076958	13-May-98	6120752	19-Sep-00	13-May-18	Granted	TAKDE/3MUS
US	DIV	01	09/440797	13-May-98	6264923	24-Jul-01	13-May-18	Granted	TAKDE/3MUS
WO	ORD	00	PCT/US98/10156	18-May-98				National Phase	NYCO/3MUS